100 search results for "%22conferences and events%22"

Virtual Events in the Era of COVID-19: Perspectives From a Virtual Interdisciplinary Wound Care Symposium

Jose Palacios, BS, Nissim Hazkour, BA, Amit Rao, MD, Mary Brennan, RN, Alisha Oropallo, MD

 

Travel restrictions during the coronavirus disease-19 (COVID-19) pandemic have made in-person conference attendance difficult, if not impossible; however, the need for organized events remains. Conferences serve as important events for exchanging knowledge, learning new skills, and socializing with peers.1 Virtual conferences have been adopted for academic events outside of the medical field and serve as an alternative to in-person events that allow people to gather despite travel restrictions.2,3 As restrictions continue to be lifted and in-person events resume, the fate of virtual events becomes unclear. While in-person conferences and symposiums had been the norm before 2020, they require abundant time commitment … read more

Predictive model identifies risk factors for major adverse limb events in diabetes

A risk score may be able to identify adults with type 2 diabetes at high risk for major adverse limb events, including in those without a history of peripheral artery disease, according to a study published in Diabetic Medicine … “This post hoc analysis of the EXSCEL trial yielded a predictive score for major adverse limb events among participants with diabetes that had a C statistic of 0.822, generally considered as very good … … continue

Inherent variations in the cellular events at the site of amputation orchestrate scar‐free

      wound healing in the tail and scarred wound healing in the limb of lizard Hemidactylus flaviviridis

 

Lizards are unique in having both – regeneration competent (tail) as well as non‐regenerating appendages (limbs) in adults. They therefore present an appropriate model for comparing processes underlying regenerative repair and non‐regenerative healing after amputation. In the current study, we use northern house gecko Hemidactylus flaviviridis to compare major cellular and molecular events following amputation of the limb and of the tail. Although the early response to injury in both cases comprises apoptosis, proliferation and angiogenesis, the temporal distribution of these processes in each remained obscure. In this regard, observations were made on the anatomy and gene expression levels of key regulators of these processes during the healing phase of the tail and limb separately. It was revealed that cell proliferation markers like FGFs were upregulated early in the healing tail, coinciding with the growing epithelium. The amputated limb, in contrast, showed weak expression of proliferation markers, limited only to fibroblasts in the later stage of healing. Additionally, apoptotic activity in the tail was limited to the very early phase of healing, as opposed to that in the limb, wherein … read more

Custom-Molded Offloading Footwear Effectively Prevents Recurrence and Amputation …

and Lowers Mortality Rates in High-Risk Diabetic Foot Patients: A Multicenter, Prospective Observational Study
Recurrence of high-risk diabetic feet, after wound, healing is a common challenge among diabetic patients. Continuous use of an offloading device significantly prevents recurrence of high-risk diabetic feet, although patient adherence is imperative to ensuring this therapy’s clinical efficacy. In this study, we explored clinical outcomes of patients with a high-risk diabetic foot who had been prescribed with custom-molded offloading footwear under different adherence conditions … read more

Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%. Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking … read more

Diabetic Limb Salvage conference joins 2023 Symposium on Advanced Wound Care (SAWC) Spring

Wound Healing Society for immersive educational experience

 

Premier annual limb salvage meeting co-locates with the leading meeting dedicated to the research, management, treatment, and prevention of wounds in April.

 

Three industry-leading wound care organizations are uniting for a conference in April 2023, focusing on wound prevention and management, research, and limb salvage. The meeting will offer the most cost-effective, comprehensive, and immersive educational event for professionals in the wound care space.

 

The Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS) is the leading meeting dedicated to the research, management, treatment, and prevention of wounds; and Diabetic Limb Salvage (DLS) is the premier annual limb salvage education event focused on wound healing and preventing amputations. The 2023 event is organized by HMP Global, the omnichannel leader in healthcare events and education, and will be held April 26-30, 2023, in National Harbor, Maryland.

 

The in-person event will provide opportunities for networking and collaboration, with an educational agenda featuring an expert lineup of faculty, in-depth discussions, and exposure to innovation, proven techniques, and effective strategies for patient care. The interdisciplinary agenda is designed for every clinician interested in wound care, including physicians, nursing professionals, physical therapists, researchers, scientists, podiatrists, and dietitians — connecting the entire wound care team with the foremost experts in the field to improve patient outcomes through education.

 

DLS Co-Chairs are Dr. Christopher E. Attinger, Chief, Division of Wound Healing at MedStar Georgetown University Hospital and professor of plastic and orthopaedic surgery, Georgetown University School of Medicine in Washington, D.C.; and Dr. John S. Steinberg, Co-Director, MedStar Health Wound Healing Institute at MedStar Georgetown University Hospital, Hospital Center Director of the Podiatric Residency Training Program, MedStar Health, and a professor of plastic surgery at Georgetown University School of Medicine.

 

“Through this collaboration, educational opportunities at the conference will focus on every aspect of wound research, prevention, and healing along with a focus on limb salvage,” said Dr. Steinberg. “We are solving the issue of access to education by uniting these three events this year to provide learners with one comprehensive event. It is an opportunity for providers to strengthen their clinical skills, invigorate their approach, and positively impact their ability to care for their patients.”

 

The collaboration with DLS will add more limb salvage-focused topics to the conference agenda, including:

 

  • Advanced Surgical Options for Lower Extremity Limb Salvage
  • Diagnosing and Managing the Charcot Foot
  • Integration of Plastic Surgery with the Limb Salvage Team
  • Endovascular Intervention

 

The WHS President is Dr. Kenneth Liechty, Division Chief of Pediatric Surgery and Director of Fetal Medicine, University of Arizona, and Surgeon in Chief of Diamond Children’s Hospital; and Co-Chairs are Dr. Daria Narmoneva, associate professor, University of Cincinnati, and Dr. Carlos Zgheib, assistant professor of surgery, University of Colorado Denver School of Medicine in Aurora.

 

“Although each of these three organizations have a unique mission, we are united in our goals of improving outcomes for patients and patient populations,” Dr. Liechty said. “We are excited to host one symposium for every member of the wound care team, allowing us to provide the highest caliber training and education that all clinicians can incorporate in their practice.”

 

SAWC Spring Co-Chairs are Dr. Robert S. Kirsner, Harvey Blank Professor and chairman, Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine; and Dot Weir, RN, CWON, CWS, clinician at Saratoga Hospital Wound Healing.

 

“We have partnered with the Wound Healing Society for 15 years, providing a robust educational experience for meeting participants, and this year’s event will be even stronger with the addition of multiple topics on amputation prevention,” Dr. Kirsner said. “No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews, and emerging research findings.”

 

For more information or to register, visit sawcspring.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

HMP Announces Launch of Post-Acute Care Symposium for Nurses

HMP, a leader in healthcare events and education, today announced the launch of the Post-Acute Care Symposium (PACS). The meeting will take place May 9–10, 2019, and will be co-located with the Symposium on Advanced Wound Care (SAWC) Spring/Wound Healing Society meeting in San Antonio, Texas.

 

PACS is uniquely designed to provide nurses with the important tools they need through a curriculum that focuses on practical, evidence-based strategies for implementing clinical practice guidelines, protocols, and care pathways for wound and incontinence interventions. The PACS Steering Committee is comprised of many of the same experts who guide the programming for the established SAWC Spring and Fall meetings.

 

“With the post-acute care setting now central to our healthcare delivery system, the time has come to provide a practical conference for nursing professionals that focuses on the day-to-day realities of patients with wound and incontinence issues,” said Catherine T. Milne, MSN, APRN, CWOCN-AP, Advanced Practice Nurse and Co-Chair for the meeting.

 

The two-day event, expected to draw approximately 250 nursing professionals, will provide a unique experience for attendees. The meeting will include a curriculum based on the nursing process method, interactive panel and case-based discussion, and “Rapid-Fire” and “Ask the Experts” sessions led by a diverse faculty that includes post-acute care educators with broad experience and practical insight. Attendees will have the opportunity to earn up to 10 CNE credits.

 

By co-locating the meeting with SAWC Spring, PACS attendees will also gain access to the world’s largest wound care exhibit hall and networking receptions as part of their registration.

 

“HMP saw an unmet need in the marketplace,” said Peter Norris, Executive Vice President, HMP. “The idea for PACS came in light of statistics showing the majority of wounds in the U.S. are being treated within the post-acute care setting by skilled nursing facility (SNF), home health (HH), and hospice providers. The educational agenda aims to provide post-acute care nursing professionals with real-world tools and strategies fit for the setting in which they care for patients on a daily basis.”

To learn more about the meeting, visit pacsymposium.com.

 

About HMP
HMP is the force behind Healthcare Made Practical—and is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include Consultant360, the year-round, award-winning platform relied upon by healthcare providers across 21 specialties; Psych Congress, the largest independent mental health meeting in the U.S.; EMS World Expo, the world’s largest EMS-dedicated event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

originally posted in PR WEB

HMP’s EMS World Expo Recognized as one of the Top 25

Fastest-Growing Trade Shows in Attendance by Trade Show News Network

 

HMP, a leading healthcare education and events company, today announced that its EMS World Expo has been recognized as one of the “Top 25 Fastest-Growing Shows in Attendance” by Trade Show News Network (TSNN). The list represents trade shows held between 2015-2017 and is ranked by overall attendance growth over that period. Winners will be honored during the 2018 TSNN Awards, taking place August 10-12 in Louisville, Kentucky.

 

Owned and produced by HMP, EMS World Expo is the largest EMS-dedicated event in the world and annually attracts thousands of emergency medical technicians and paramedics. With more than 250 educational sessions, EMS World Expo sets the standard in EMS education, offering the latest information, tools, technologies, and trends in prehospital care.

 

“Being recognized by Trade Show News Network as one of the fastest-growing trade shows in the U.S. is a great honor,” said Joshua D. Hartman, MBA, NRP, vice president, public safety division, HMP. “The growth reflects our commitment to providing quality education in prehospital care to EMS professionals in the U.S., and around the world.”

 

In 2017, more than 5,700 attendees from 50 countries participated in EMS World Expo. In addition to a trade show floor spanning 70,900 sq. ft., the 2017 exposition featured more than 360 exhibitors showcasing innovative products, services, and technologies to improve patient care, enhance provider safety, and increase operational efficiencies.

 

The 2018 EMS World Expo will take place October 29-November 2, in Nashville, Tennessee. For more information, visit emsworldexpo.com.

 

About EMS World Expo
As the largest EMS-dedicated event in the world, EMS World Expo, hosted in partnership with the National Association of Emergency Medical Technicians (NAEMT), annually attracts more than 5,700 EMS professionals. EMS World Expo sets the standard in EMS education, offering the training professionals need to do their jobs today, with the progressive curriculum and technology that provides the solutions for tomorrow.

 

About HMP
HMP is the force behind Healthcare Made Practical—and is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include Consultant, the monthly, award-winning journal relied upon by primary care providers; Psych Congress, the largest independent mental health meeting in the U.S.; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Original post in PRWeb

HMP Global launches Great Debates & Updates program focusing on Diabetic Foot Syndrome

HMP Global, the omnichannel leader in healthcare events and education, today announced the launch of a new program offering professionals who treat diabetic foot syndrome the opportunity to debate the most controversial topics in treatment options and gain knowledge from one another.

 

Great Debates & Updates in Diabetic Foot will be held December 2-3 in San Antonio, Texas. The unique, debate-style format will include dynamic presentations and interactive debates, while also diving into the long history of podiatry culture in San Antonio.

 

“The agenda will feature a mix of clinical updates and lively debates on provocative scientific topics impacting the field, including emerging concepts and treatment options for the diabetic foot,” said Dr. Lawrence A. Lavery, UT professor, board-certified podiatrist at UT Southwestern Medical Center, and event co-chairman. “We are excited to lead this inaugural event and provide a unique, interactive experience to the attendees, with several opportunities to network with faculty, industry, and colleagues.”

 

This year is the 50th anniversary of the podiatry residency program at the University of Texas Health Science Center in San Antonio, Lavery said, a milestone which will be celebrated at the GDU in Diabetic Foot event.

 

“There is a rich history of podiatry culture and diabetic foot research in Texas,” said Dr. Lee C. Rogers, event co-chairman and Chief of Podiatry and Associate Professor in the Department of Orthopedics at the University of Texas Health. “The Diabetic Foot Ulcer Classification System is a proven, effective, and widely used classification system for predicting hospitalization and lower extremity amputation. We look forward to discussing this, along with other important treatment tools and techniques, during the new program.”

 

GDU in Diabetic Foot is designed for the wide spectrum of medical professionals who diagnose and manage the diabetic foot, including podiatrists, wound care physicians, physical therapists, physicians-in-training, nurse practitioners, and physician assistants. The in-person meeting will allow attendees more opportunities for networking and engaging with colleagues and faculty experts.

 

“The GDU brand offers an educational experience unlike any other,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “These unique, debate-style conferences provide a comprehensive learning experience covering the latest scientific updates and controversial issues emerging in different fields. We are excited to introduce the GDU brand through important education about managing and treating the diabetic foot.”

 

GDU in Diabetic Foot offers a maximum of 9 hours of continuing education credit. Exhibit space, attendee engagement options, and branding opportunities are available to organizations interested in participating in the event.

 

For more information or to register, visit gdudiabeticfoot.com.

 

About HMP Global
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

HMP Global’s SAWC Spring | WHS announces record number of wound care abstract submissions for 2023 meeting

More than 500 abstracts featuring late-breaking wound care research, new advances and techniques to improve care and outcomes for patients were submitted for poster at the 2023 event, co-located with the Diabetic Limb Salvage meeting.

 

HMP Global, the leading omnichannel healthcare events and education company, today announced that its 2023 Symposium on Advanced Wound Care (SAWC) Spring and Wound Healing Society (WHS) received a record-breaking number of abstract submissions for the event taking place April 26-30, strengthened by a new partnership co-locating the symposium with the Diabetic Limb Salvage conference.

 

Now in its 36th year, SAWC Spring | WHS is the leading meeting dedicated to the research, management, treatment, and prevention of wounds; and through the partnership with DLS, this year’s event will feature more limb salvage-focused topics on the conference agenda. The meeting is the premier multidisciplinary forum to connect practitioners, researchers, and students with the foremost experts in wound care to improve patient outcomes through education.

 

Symposium participants will have access to 450 posters featuring late-breaking wound care research, new advances, strategies, and techniques to improve care and outcomes for patients. More than 500 abstracts — a record number — were submitted to undergo the peer review process for poster consideration.

 

In addition to presenting posters in person at SAWC Spring | WHS | DLS, wound care researchers can elevate their work further by submitting abstracts for publication in the field’s preeminent, peer-reviewed journal WOUNDS, focusing on the latest advances in wound care and wound research. WOUNDS is indexed in MEDLINE/PubMED and publishes research and commentary on tissue repair and regeneration, biology and biochemistry of wound healing, and clinical management of various wound etiologies. Submission information and guidelines are available on HMP Global’s Wound Care Learning Network.

 

“The record-breaking number of abstract submissions this year is a testament to the dedication of the wound care community to advancing their knowledge and skills,” said Tiffney Oliver, Vice President, Wound Care Learning Network, HMP Education. “For our 2023 meeting, we are excited to offer a world-class lineup of educational sessions as well as a record number of abstracts about the latest research in wound care.”

 

Submitted abstracts are blind reviewed by a panel of expert judges, based on specific criteria for the category in which it was submitted. Researchers may also be considered for poster grand rounds, oral abstracts, SAWC Young Investigator, and highest scoring abstract honors.

 

“We are excited to host one symposium for every member of the wound care team, allowing us to provide the highest caliber training and education that all clinicians can incorporate into their practice,” said WHS President Dr. Kenneth Liechty, Division Chief of Pediatric Surgery and Director of Fetal Medicine, University of Arizona, and Surgeon in Chief of Diamond Children’s Hospital. “The quantity and high caliber of the posters presented this year spotlights the most up-to-date research on wound care and limb salvage. This level of exposure to innovation is unparalleled in the wound care community.”

 

Posters will be on view from 7:30 a.m. to 5 p.m. Friday, April 28, and from 7:30 a.m. to 5 p.m. Saturday, April 29. In addition, SAWC Spring | WHS | DLS participants will have the opportunity to interact with the researchers during the Poster Reception and Awards Presentation from 7:15-8:30 p.m. on April 28, presented by WOUNDS.

 

Educational Program

The SAWC Spring | WHS | DLS agenda features more than 80 high-impact sessions from expert presenters led by the giants and emerging voices in the field, providing more than 25 CME/CE credits. Participants will have access to sessions in traditional as well as new formats, including hands-on workshops, rapid-fire, case-based, and patient panels. Learning tracks encompass the business of wound care as well as separate tracks through DLS and WHS.

 

“We have partnered with the Wound Healing Society for 15 years, providing a robust educational experience for meeting participants, and this year will be even stronger with the addition of multiple topics on amputation prevention, said SAWC Spring Co-Chair Dr. Robert S. Kirsner, Harvey Blank Professor and chairman, Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine. “No other wound care conference offers this level of education, advanced state-of-the-art clinical reviews, and emerging research findings.”

 

The interdisciplinary agenda is designed for every aspect of wound research, prevention, and healing, with an important focus on limb salvage. Sessions are designed for all members of the wound care team, including physicians, nursing professionals, podiatrists, physician assistants, physical therapists, researchers, scientists, dietitians, and healthcare, sales, and marketing professionals.

 

For more information or to register, visit sawcspring.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

 

This article was originally published here

Development of a prediction model for foot ulcer recurrence in people with diabetes using …

easy-to-obtain clinical variables
We used data from a prospective analysis of 304 people with foot ulcer history who had 18-month follow-up for ulcer outcome. Demographic, disease-related and organization-of-care variables were included as potential predictors. Two logistic regression prediction models were created: model 1 for all recurrent foot ulcers (n=126 events) and model 2 for recurrent plantar foot ulcers (n=70 events). We used 10-fold cross-validation, each including five multiple imputation sets for internal validation. Performance was assessed in terms of discrimination using area under the receiver operating characteristic curve (AUC) (0–1, 1=perfect discrimination), and calibration with the Brier Score (0–1, 0=complete concordance predicted vs observed values) and calibration graphs … read more

Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

admin
  • Poster highlights pravibismane’s MIC activity in testing against aerobic and anaerobic pathogens isolated from diabetic foot infection patients
  • Pravibismane demonstrated potent, broad-spectrum activity against a wide range
    of pathogens, including MRSA, MSSA, and P. aeruginosa

BOZEMAN, Mont., May 10, 2023 /PRNewswire/ – Microbion Corporation today announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands. The poster highlights pravibismane’s activity versus comparator antibiotics against pathogens isolated from diabetic foot infection (DFI) patients in an earlier Phase 1b clinical study.

Poster Details:
Representative image (CNW Group/Microbion Corporation)

Representative image (CNW Group/Microbion Corporation)

Title: Broad-Spectrum, Potent Activity of Pravibismane Versus Comparators Against Diabetic Foot Ulcer Infection Patient Isolates Collected in a Phase 1b Study

Presenter: Dr. Jeff Millard, CSO

Poster Highlights:
  • Most common pathogens isolated from DFI subjects (N = 44) at baseline were: methicillin-susceptible Staphylococcus aureus [MSSA (25%)]; methicillin-resistant Staphylococcus aureus [MRSA (18.2%)]; Enterococcus faecalis (13.6%); and Pseudomonas aeruginosa (11.4%).
  • Mean pravibismane minimum inhibitory concentration (MIC) (µg/mL) for S. aureus MSSA was 0.21, S. aureus MRSA was 0.17, E. faecalis was 2.53, and P. aeruginosa was 1.43.
  • Mean pravibismane MICs for 12 of the 13 anaerobic bacteria was ≤1 µg/mL, including against Finegoldia magna and Anaerococcus spp.
  • Pravibismane exhibited similar or lower MIC relative to a panel of comparator antibiotics, including (but not limited to) levofloxacin, linezolid, clindamycin, and piperacillin-tazobactam, against Gram-positive and Gram-negative, susceptible and resistant, aerobes and anaerobes.

"We are pleased that pravibismane demonstrated extremely potent MIC activity against clinical DFI isolates, which was in line with in vitro AST microbial pre-clinical studies," said Dr. Jeff Millard, CSO of Microbion Corp. "Diabetic foot infections are often infected by several different bacterial species concurrently, which may change over the chronicity of the wound, from predominantly aerobic to anaerobic. We believe pravibismane’s potent broad-spectrum activity is potentially a key treatment advantage since a single agent could eradicate both aerobic and anaerobic bacteria, thereby decreasing the need for multiple systemic therapies."

Bacterial cultures for this study were grown from swabs collected at the wound bed at baseline visit and antimicrobial susceptibility testing (AST) was performed on isolated pathogens. Pathogen isolation and AST was performed at Investigational Health Management Associates (IHMA, IL), using the Clinical & Laboratory Standards Institute (CLSI) standard methods.

Topical pravibismane has received QIDP and Fast Track drug designation from the US FDA for the adjunctive treatment of moderate and severe diabetic foot ulcer infections. Topical pravbismane is currently enrolling in a Phase 2 clinical study to further evaluate its safety and efficacy in subjects suffering from moderate infections associated with chronic diabetic foot ulcers.

About Microbion

Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.

For more information visit: www.microbioncorp.com.

Safe Harbor Statement

Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Microbion Corporation

HMP Global expands value for podiatry community with launch of PodiatrySource product guide and Podiatry Learning Network

The platform serves as a comprehensive resource for podiatry news and information to aid clinical decision-making and improve patient outcomes

 

MALVERN, Pa., July 12, 2022 /PRNewswire-PRWeb/ — As healthcare professionals across the podiatry community manage an ever-changing and complex field, HMP Global, the leading healthcare event and education company, today announced the launch of two value-added offerings, PodiatrySource and the Podiatry Learning Network.

 

The Podiatry Learning Network serves as the premier digital hub for podiatrists and offers direct access to clinically relevant news and information, expert perspectives, and continuing education. The network joins HMP Global’s portfolio of well-respected learning platforms dedicated to serving as online information hubs, and is a singular destination offering practical, relevant content and education guided by podiatry professionals.

 

Visitors to the new network can create a customized experience, selecting topic preferences most pertinent to them; receive regular e-mail updates with breaking news and carefully created content; grow professionally with the network’s repository of education; and connect with other podiatry colleagues around the world through the platform’s networking options.

 

“With the creation of the Podiatry Learning Network, HMP Global is delivering a single, definitive resource that podiatry professionals can rely upon to access important clinical knowledge on new therapies and treatments on a broad spectrum of topics, and enjoy a highly specialized content experience,” said David DePinho, President, HMP Global. “Healthcare professionals in the podiatry field will benefit from this comprehensive resource to receive ongoing professional development and provide the highest quality of patient care.”

 

PodiatrySource

 

HMP Global is also launching PodiatrySource, a one-stop resource with independent, clinically reviewed, and unbiased information to help clinicians make informed decisions about podiatry care products.

 

Powered by Podiatry Today, the award-winning, premier publication and online platform, PodiatrySource will reach buyers with the trusted information they need to act and make decisions about product selection and purchasing. It will provide 24/7 access to information on an interactive, user-friendly digital platform.

 

“The Podiatry Today audience is invested in providing patients optimal care and staying abreast of the latest product offerings across the field is part of how they achieve this goal,” said Jennifer Spector, DPM, FACFAS, Managing Editor of Podiatry Today, a trusted educational resource in podiatric medicine and surgery that provides engaging content to help clinicians improve patient care. “Creating PodiatrySource is a natural synergy of the education provided by Podiatry Today, with robust information about innovations provided by companies in the podiatric space.”

 

PodiatrySource currently highlights products focused on the office-based practitioner, and future updates will include more products and companies to best serve the full foot and ankle medical and surgical community, Spector said. PodiatrySource is open access with no subscription required for use. Industry contacts may submit product information through the website, and enhanced opportunities are available.

 

“PodiatrySource is designed to quickly become podiatry’s most relied upon tool to navigate the many options for products and services available to healthcare professionals in the podiatry community,” DePinho said. “It offers credible, trusted, non-biased clinically reviewed content that clinicians can use during the decision-making and purchasing processes.”

 

The new PodiatrySource resource guide is modeled after the highly successful WoundSource product reference guide. First published in 1998, WoundSource now includes more than 1,700 products manufactured by more than 200 wound care companies. Its digital companion, woundsource.com, includes product lists and reviews as well as articles, blogs by industry thought leaders, white papers, and other educational resources for wound care professionals.

 

For more information about PodiatrySource and the Podiatry Learning Network, visit hmpgloballearningnetwork.com/site/podiatrynet.com.

 

ABOUT HMP GLOBAL
HMP Global is the force behind Healthcare Made Practical — and is an omnichannel leader in healthcare content, events, and education, with a mission to improve patient care. The company produces accredited medical education events — in person and online via its proprietary VRTX virtual platform — and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include the HMP Global Learning Network, healthcare’s most comprehensive source for news and information; Psych Congress, the largest independent mental health meeting in the U.S.; the Evolution of Psychotherapy, the world’s largest independent educational event for mental health professionals; the Leipzig Interventional Course (LINC), the leading, global gathering for interdisciplinary cardiovascular specialists; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

 

Media Contact

Sandi Beason, APR, HMP Global, (601) 573-1737, pr@hmpglobal.com

 

SOURCE HMP Global

Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)

Lakewood-Amedex’s Second Clinical Trial for DFU Using New Nu-3 Gel Formulation Top Line Results Expected in December 2022

 

SARASOTA, Fla., April 5, 2022 /PRNewswire/ — Lakewood-Amedex, Inc., a privately held, clinical stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins®, announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU). More than 34 million adults in the United States have diabetes mellitus (Source: CDC), and complications of DFU are responsible for about 85% of the non-traumatic lower extremity amputations per year, creating a tremendous morbidity, mortality, and financial burden on the healthcare system.

 

The Phase 2 study is a randomized, multi-center, double-blind, placebo-controlled, dose-escalating study to evaluate the safety and tolerability of topically applied Bisphosphocin Nu-3 gel on Type I or II diabetes mellitus patients with chronic DFU. During all clinic visits, the patients’ ulcers will be examined for any changes in the area and depth of the ulcer and microbiological control will be assessed.

 

Steve Parkinson, President & CEO of Lakewood-Amedex, said, “We are very pleased to be embarking upon our second clinical trial in treating DFUs. In our previous experience evaluating Nu-3 for the treatment of patients with infected diabetic foot ulcers, Nu-3 was well-tolerated with no reported adverse events related to treatment. While this previous dose-escalating study was not powered to generate statistically significant efficacy data, it did demonstrate an encouraging efficacy trend. Patients treated with 2% Nu-3 solution for seven days had a 65.5% reduction in ulcer area versus a 29.9% reduction in the placebo arm, as measured 14 days after treatment began. In addition, 62.5% of patients treated with 2% Nu-3 saw a reduction in the microbiological load, versus 20% in the placebo. Now our Phase 2 dose-escalating study will build on the foundation of the previous clinical trials by using a longer treatment duration of 28 days, a higher concentration of 5% followed by 10% Nu-3, as well as an improved Nu-3 gel formulation, all of which we expect will offer a better delivery of Nu-3 and treatment of nonhealing wounds. The impact of both topical and systemic infections remains a tremendous burden on the healthcare system. We believe our commitment to further developing our proprietary, antimicrobial Bisphosphocins technology platform with efficient, localized treatment of serious infections, often caused by antibiotic-resistant pathogens, both gram-positive and gram-negative, will enable healthcare providers to more safely and effectively address a host of bacterial infections that are currently proving challenging using conventional approaches.”

 

“Dr. Felix Sigal, who is one of the most distinguished specialists in the field of diabetic limb salvage, is on staff at both the Hollywood Presbyterian Medical Center and the California Hospital Medical Center. He focuses on wound care and diabetic limb salvage, while pursuing his interest in clinical research to enable better treatment options for his patients. We are pleased to report that Dr. Sigal has now enrolled the first patient in this Phase 2 study evaluating the use of Nu-3 gel in the treatment of diabetic foot ulcers,” said Sumita Paul, MD, MPH, MBA, Chief Medical Officer & Senior Vice President of Research & Development at Lakewood-Amedex Inc. “There will be 12 patients treated with the Nu-3 gel in each of the two cohorts and with a smaller placebo treated group.”

 

About Lakewood-Amedex, Inc.

Lakewood-Amedex is a privately held, clinical stage pharmaceutical company developing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins. The company’s products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets. The company’s lead therapeutic candidates are novel synthetic broad-spectrum antimicrobials proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and all fungal strains tested. Nu-3 has already completed a Phase 2a clinical trial in patients with infected diabetic foot ulcers. For more information, https://lakewoodamedex.com.

 

This press release contains forward-looking statements that can be identified by terminology such as “expects,” “potential,” “suggests”, “may”, “will” or similar expressions. Such forward-looking statements regarding our business, which are not historical facts, are “forward-looking statements” that involve risk and uncertainties, which could cause the Company’s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

 

Contacts
Tiberend Strategic Advisors, Inc.

 

Investors
Lisa Sher
lsher@tiberend.com

 

Media
Dave Schemelia
dschemelia@tiberend.com

 

SOURCE Lakewood-Amedex Inc.

 

This article was originally published here

Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy

in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

 

Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

 

BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

 

“We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

 

Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

 

Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

 

In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

 

DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

 

References:

  1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
  2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
  3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
  4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
  5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
  6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
  7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
  8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

 

About Microbion
Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

 

About CUBRC
CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

 

Safe Harbor Statement
Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

US Government Funding Disclaimer
Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

 

SOURCE Microbion Corporation

This article was originally published here

About Us

Wound Care Weekly is the world’s most comprehensive source of all things wound care, news, events, articles, video, etc. Wound Care Weekly is updated daily and our newsletter is delivered…

TECHNOLOGY EFFECTIVE AGAINST ANTIBIOTIC-RESISTANT PATHOGEN

RESEARCH SHOWS ANTIBIOTIC-RESISTANT CANDIDA ALBICANS IS KILLED BY EXPOSURE TO VOMARIS BIOELECTRIC V.DOX™ TECHNOLOGY

Vomaris Innovations, Inc. announced today the publication of results demonstrating that the company’s bioelectric V.Dox™ Technology is effective in killing antibiotic-resistant Candida albicans pathogens. The manuscript, “Ketoconazole Resistant Candida albicans is Sensitive to a Wireless Electroceutical Wound Care Dressing,” was published in Bioelectrochemistry https://doi.org/10.1016/j.bioelechem.2021.107921The research was led by Chandan K. Sen, Ph.D., Director of the Indiana Center for Regenerative Medicine and Engineering at Indiana University and Distinguished Professor and J. Stanley Battersby Professor of Surgery at the IU School of Medicine.

 

Antibiotic resistance is one of the greatest global public health challenges of our time1. Every year, more than 2.8 million antibiotic-resistant infections occur in the United States2, and 700,000+ people die globally3. Meanwhile, the discovery of novel antimicrobials is not keeping up with the emergence of new superbugs.1,4 “Antibiotic resistance is growing, and we are fast running out of treatment options. If we leave it to market forces alone, the new antibiotics we most urgently need are not going to be developed in time,” predicts Dr. Marie-Paule Kieny, WHO’s Assistant Director-General for Health Systems and Innovation.

 

In the study, researchers sought to determine whether the wireless electroceutical wound care dressing or “WED”, was effective in managing pathogenic molecular processes employed by ketoconazole-resistant yeast Candida albicans. Candida albicans poses a major threat to skin and wound infection. It’s typically treated topically with the drug ketoconazole. However, ketoconazole-resistant pathogens are an emerging threat in the management of skin infection.  The authors believe that the emergence of multidrug resistance in Candida albicans warrants the need for alternative, non-pharmacological methods of wound treatment.

 

Vomaris’s WED, powered by V.Dox™ Technology, is a proprietary pattern of embedded microcell batteries that wirelessly generates a low level of electricity in the presence of moisture.  The research team used an in vitro model to test WED alone, ketoconazole alone, and the combination of WED + ketoconazole, against ketoconazole-resistant Candida albicans. Three controls were used, including no treatment, plain polyester fabric, and a fabric impregnated with silver.

 

The researchers found that WED functioned in a multi-pronged manner to effectively treat ketoconazole-resistant Candida albicans. Findings included:

  • Prevented hyphal growth. The development of hyphae (long, branched filaments) is a critical part of albican’s growth cycle. Stopping hyphal growth prevents C. albicans from causing infection and subsequent tissue damage.
  • Impaired efflux pump system. Damaging this system prevents albicans from rejecting helpful antibiotics.
  • Damaged cell wall integrity. Weakening the cell wall structure allows antibiotics to reach the pathogen.
  • Disrupted biofilm formation. C. albicans develops a biofilm ‘shield’ to protect it from immune system and antibiotic attack. WED interfered with its ability to form biofilm.
  • In contrast, silver alone was ineffective in all experiments.

“This work presents clear evidence that the wireless electroceutical dressing kills ketoconazole-resistant Candida albicans,” said Dr. Sen. “Our findings introduce the option of a novel biophysical solution for fighting chronic wound infection in which antibiotic-resistant pathogens are prevalent.”

“These latest findings by Dr. Sen and team add to our growing body of evidence on the significant role electricity can play in combatting antibiotic-resistant pathogens. In this era of antibiotic stewardship, a wound care product that kills pathogens without the use of antibiotics is an important technological breakthrough,” said Vomaris President and CEO Michael Nagel. “Our V.Dox Technology is already FDA cleared and is the only bioelectric product of its kind in the marketplace today.”

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report.

About Vomaris

Vomaris Innovations, Inc. (www.vomaris.com) is a privately held medical device company specializing in bioelectric technology that is redefining infection control and wound healing. Vomaris’s patented V.Dox™ Technology is defining the bioelectric wound care market; it’s the only platform in the world that powers a new generation of antimicrobial dressings for the wound and incisional care markets. The company currently has six randomized controlled trials in progress.

Vomaris and V.Dox and respective logos are trademarks of Vomaris Innovations, Inc.

 

High School Senior Awarded Scholarship for Creating an Orthotic

that detects and prevents diabetic foot ulcers.

 

Western Albemarle high school senior Meg Richey is awarded a scholarship at the 18th annual Emily Couric Leadership Forum at the Omni Charlottesville Hotel on Wednesday. Richey, who will attend Stanford University, was awarded a scholarship of $30,000 for her work creating an orthotic that detects and prevents diabetic foot ulcers.

Meg Richey was this year’s main award winner, and she received a $30,000 scholarship.

 

A senior at Western Albemarle High School who plans to study computer science at Stanford University, Richey has a provisional patent for a medical device and is the youngest person to study at the University of Virginia’s Biomedical Engineering Design Lab.

 

Her device, named after her childhood bus driver, Mike Morris, was envisioned after Morris died after developing a diabetic foot ulcer.

 

“He was the first and last person we saw during the day,” Richey said. “It was so important, especially in middle school, to feel like someone genuinely cared.”

 

The Morris Orthotic is a custom foot insole with sensors that detect changes in pressure at the bottom of a diabetic patient’s foot. Possibly the first custom-fit orthotic with sensor technology, it might alert a patient to life-threatening conditions that are hard to detect … read more

SGLT2 inhibitor therapies may raise risk for amputation

Adults with type 2 diabetes and established CVD prescribed SGLT2 inhibitor therapy have a twofold increased risk for lower-limb amputation and diabetic ketoacidosis compared with patients prescribed a GLP-1 receptor agonist, according to study findings presented at the European Society of Cardiology Congress.

“Sodium glucose cotransporter 2 inhibitors are playing an increasingly prominent role in the treatment of diabetes, following the reduced risk of major adverse cardiovascular events and heart failure outcomes seen in the EMPA-REG Outcome trial with empagliflozin [Jardiance, Boehringer Ingelheim] and in the CANVAS study with canagliflozin [Invokana, Janssen],” Peter Ueda, MD, PhD, from the department of medicine at the Karolinska Institute in Solna, Sweden, said during a presentation here. “Concerns exist regarding the safety of the drugs, with signals of serious adverse events emerging from clinical trials, case reports and observational studies.” … read more

HMP’s Wound Certification Prep Course Announces 12 New Locations for 2019

HMP, a leader in healthcare events and education, today announced twelve new course locations for the 2019 Wound Certification Prep Course (WCPC), the leading comprehensive wound care training program. Based upon the ongoing demand for clinicians to possess increased specialized knowledge in wound management, WCPC will be expanding its course to 12 cities nationwide, including San Francisco, Philadelphia, Nashville, and Chicago. Furthermore, three of the 12 programs will be co-located with HMP’s leading medical conferences: the Symposium on Advanced Wound Care (SAWC) Spring and Fall meetings, the world’s largest wound care educational events; and the Amputation Prevention Symposium (AMP) … read more

HMP’s Why Wound Care?™

Initiative Launches Web Portal for Medical Students

 

In an effort to further prepare medical professionals about the proper management and treatment of patients with wounds, HMP, a leading healthcare event and education company, today announced the launch of a new web portal designed exclusively for medical students as part of its Why Wound Care? (WWC) initiative.

 

Created in 2015, the Why Wound Care? initiative informs medical and nursing students, recent graduates, and faculty about rewarding careers in wound care while offering educational resources to supplement current academic curricula where wound care education may be limited.

 

With the development of the new portal, medical students and faculty now have access to the following complimentary, evidence-based wound care resources:

 

-Sixteen video modules covering the fundamentals of wound care, including
Burns, Surgical Wound Closure, Wound Epidemiology, Pressure Injuries, Diabetic Foot Ulcers, Atypical Wounds, Wound Infections, and more;
-Downloadable PDF’s of all 25 chapters of Chronic Wound Care: The Essentials e-Book, the “gold standard” of wound care textbooks;
-Information about other continuing education resources, including wound care conferences and medical journals.

 

“The launch of the medical student portal greatly expands the scope of our Why Wound Care? initiative,” said Peter Norris, executive vice president, HMP. “Three years ago, we introduced WWC to nursing students. Since then, the portal has become a go-to source of free wound care content with thousands of visitors accessing modules and other materials. With the addition of the medical student portal, we are able to extend the reach of wound care education to new audiences to ultimately help improve the care of patients who suffer from acute or chronic wounds.”

 

The WWC medical student advisory board—comprised of 16 world-class wound care physician specialists affiliated with some of the top medical schools in the U.S., including Harvard, Penn, Stanford, Columbia, Miami, and Georgetown—contributed to the development of the materials.

 

“This project represents our opportunity to give back to future generations of medical students,” said Robert Kirsner, MD, PhD, Chair and Harvey Blank Professor, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, and chair, WWC medical student advisory board. “For more than 30 years, I’ve had the good fortune to practice wound care, conduct research, and educate students, residents, and fellows as a faculty member at the University of Miami. Wound care will only receive increased attention in clinical practice due to the aging population and the rising incidences of Diabetes Mellitus and obesity. Medical students now have an excellent resource by which to learn more about wound care to either better educate themselves about evidence-based treatment and management of chronic wounds, or to consider becoming a practicing wound care physician.”

 

To learn more about Why Wound Care?, or to take advantage of these free resources, please visit whywoundcare.com.

 

About HMP
HMP is the force behind Healthcare Made Practical—and is a multichannel leader in healthcare events and education, with a mission to improve patient care. The company produces accredited medical education events and clinically relevant, evidence-based content for the global healthcare community across a range of therapeutic areas. Its brands include Consultant360, the year-round, award-winning platform relied upon by primary care providers and other specialists; Psych Congress, the largest independent mental health meeting in the U.S.; EMS World Expo, North America’s largest EMT and paramedic event; and the Symposium on Advanced Wound Care (SAWC), the largest wound care meeting in the world. For more information, visit hmpglobal.com.

Original release from PRWeb

Resources

and events company Promover un mejor manejo de las heridas y estomas de eliminación a través de iniciativas de práctica basada en evidencia, educación, políticas públicas e investigación, a través…

Organogenesis Holdings Inc. to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

CANTON, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference, which is being held at the Sheraton New York Times Square Hotel in New York, NY from September 12th-14th. Management will host a fireside chat on Tuesday, September 13th at 11:45 a.m. Eastern Time.

 

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. An archive of the webcast will be available for replay following the conference for approximately 30 days.

 

About Organogenesis Holdings Inc.

 

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

Orpyx launches Orpyx SI Flex Sensory Insoles and Diabetes Healthspan Extension care model

13-Jun-2022 8:05 AM EDT, by Orpyx Medical Technologies Inc.

 

Newswise — CALGARY, AB, June 13, 2022 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services. This remote monitoring program drives engagement and extends mobility for people living with diabetes by transforming patient care through real-world patient data, analytics, and coaching.

The Orpyx SI® Flex Sensory Insoles help reduce the risk of plantar complications by monitoring plantar pressure, adherence, step count, and temperature data for patients that need preventative care.

“The launch of Orpyx SI Flex is our next step in enabling Diabetes Healthspan Extension™,” stated Dr. Breanne Everett, CEO and co-founder of Orpyx. “In North America, one-third of people are living with diabetes or pre-diabetes which often requires juggling an overwhelming number of actions, measurements, and appointments. By taking a holistic approach through a digital care platform we can dramatically improve upon the current standard of care. We are starting with foot care through robust data generation via our sensory insoles, and supporting patient engagement through RPM and coaching.”

 

The Orpyx SI Flex Sensory Insole system is a wearable technology designed to help prevent plantar foot complications for at-risk patients with peripheral neuropathy. “It is like having a supercomputer on the bottom of each foot,” said Denis Brisson, Chief Operating Officer at Orpyx. “Plantar pressure is a leading cause of foot ulceration so by measuring sustained high pressure we can help eliminate the root cause of many of these wounds before they happen.”

 

Along with pressure, the system captures wear time to determine how compliant the patient is to their provider’s treatment plan, step count to help dose activity levels, and temperature the last line of defense to indicate when inflammation is present and tissue damage is occurring. The ultra-thin, prefabricated sensory insoles fit in most every-day footwear, making them practical and comfortable for a broad range of patients.

 

Orpyx is changing the conversation by initially focusing on preventing foot ulceration by generating the most robust set of real-world plantar data. Historically, the focus has been on how to treat patients’ foot ulcers after they have already formed, with disappointing results as 25% of people with diabetes will develop an ulcer during their lifetime. These ulcers have a detrimental impact on patients’ mobility often resulting in life-shortening events such as amputation which can cause a ripple effect of social isolation, mental health challenges, and in the most complex situations death. Most diabetic foot ulcers (DFUs) are preventable, so we are on a mission to help patients and providers achieve improved, sustainable outcomes.

 

“Healthcare systems cannot sustain the current clinical strain of managing the 34 million people with diabetes in the US and the resulting $176B in financial costs. One third of this cost is attributed to lower limb care which is why this is such important work,” continued Dan Hughes, Orpyx’s Chief Commercial Officer. “Orpyx SI Flex Sensory Insoles and our new RPM services were specifically developed to meet these challenges head-on. Our insoles will play a significant role in the diabetic care pathway enabling patients to take proactive steps to manage their diabetes while reducing the total cost of care for Commercial Payers and Integrated Delivery Networks across the United States. Ultimately, this technology drives alignment and better outcomes for patients, providers, payers, and physicians.”

 

Healthcare providers seeking additional information to help their patients prevent DFUs can learn more about the new Orpyx SI Flex Sensory Insoles at https://www.orpyx.com/orpyx-si-flex-sensory-insoles.

 

About Orpyx Medical Technologies Inc.

 

Founded in 2010, Orpyx® Medical Technologies Inc. (“Orpyx”) is a Calgary-based digital health company. We take a holistic approach to remote “anywhere” care, which includes the company’s proprietary, imperceptible sensory insole platform that detects pressure, temperature, gait, activity, and movement symmetry. Our comprehensive Orpyx SI® Sensory Insole system enables continuity of care between visits to provide optimal remote care for people living with diabetes or recovering from surgery. The patient’s data is uploaded to the Orpyx SI cloud-based dashboard, where accredited healthcare practitioners remotely monitor it. The remote monitoring team communicates directly with the patient between care visits to ensure ongoing continuity and quality of care.

 

Visit www.orpyx.com for more information.

MolecuLightDX™ Wins Award as a Top Innovation in Wound Care 2022 From Wound Management & Prevention Journal

TORONTO, July 7, 2022 /PRNewswire/ – MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of wounds containing elevated bacterial loads, announces that it has been selected for a “Top Innovation in Wound Care 2022″ Award from Wound Management & Prevention (WMP) Journal for its MolecuLightDX™ device.

 

MolecuLightDX™ Wins Award as a Top Innovation in Wound Care 2022 From Wound Management & Prevention Journal (CNW Group/MolecuLight)

WMP provides news and information for professionals in wound care, ostomy care, incontinence care, and related skin and nutritional issues, and features ground-breaking research, peer-reviewed articles, and clinical discussions on topics relevant to the field. WMP and the Wound Care Learning Network are published by HMP Global, an omnichannel leader in healthcare content, events, and education.

 

MolecuLightDX was selected as a winner this year for its novel utility to provide a point-of-care tool to clinicians worldwide that enables the detection of elevated bacterial burden in wounds. Based on its extensive body of evidence and interviews with clinicians using it, the MolecuLight device is changing the standard of care in wound care.

 

“Wound Management & Prevention is dedicated to featuring the top innovations in wound care,” said Christiane Odyniec, Managing Editor. “Each July, the WMP Editorial Board nominates the newest innovations in the field of wound care, with the goal of sharing information to improve patient care. MolecuLightDX was nominated by our board for its innovation and practical applications, and we are pleased to recognize MolecuLight Inc. in this way.”

 

As part of WoundCon Summer 2022’s Technology Innovation Theatre, WMP will be hosting a webinar on “Wound Management & Prevention’s Top Innovations in Products & Care of 2022” on Thursday, July 14th at 1:30 PM EST. Five of the winning products will be featured, including the MolecuLightDX.
In this webinar, Dr. Charles A. Andersen, Medical Director of the Wound Care Clinic and Limb Salvage Program at Madigan Army Medical Center in Tacoma, WA will be speaking on his experience with MolecuLight and how it is changing his clinical practice. “Using MolecuLight has revolutionized our wound care practice and now allows us to provide proactive wound care,” says Dr. Andersen. “It’s a game-changer.”

 

Registration for the webinar is accessible here.

 

The MolecuLight i:X and DX devices are supported by a broad body of clinical evidence showing how they help to inform and improve clinical decision-making in wound care. This list of clinical evidence includes over 60 peer-reviewed publications and 1,500 studied wound patients.

 

About MolecuLight Inc.
MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight’s suite of commercially released devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, provide point-of-care handheld imaging devices for the global wound care market for the real-time detection and localization of elevated bacterial load in wounds and for digital wound measurement. MolecuLight procedures performed in the United States can benefit from an available reimbursement pathway including two CPT® codes for physician work to perform “fluorescence imaging for bacterial presence, location, and load” and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other markets with globally relevant unmet needs including food safety, consumer cosmetics and other key industrial markets.

 

  • Image (Badge for a “Top Innovation in Wound Care 2022” Award from Wound Management & Prevention (WMP) Journal): Download
  • Image (MolecuLightDX point-of-care device for imaging elevated bacterial loads in wounds and for performing stickerless digital wound measurement): Download  

 

SOURCE MolecuLight

Global focus: MASD

Special Report on MASD written by Elizabeth Faust, MSN, CRNP, CSWS, CWOCN-AP, MAPWCA; Siobhan McCoulough, CNS; and Patricia Idensohn, CNS

 

Moisture-associated Skin Damage (MASD), as the name suggests, occurs when exposure to a moisture source results in a breakdown of skin integrity. MASD is an umbrella term for a number of conditions including incontinence-associated dermatitis, peri-stomal skin damage, peri-wound skin damage and intertrigo. These conditions can impact greatly on patients so protecting the skin from damage and promoting wound healing are integral parts of skin and wound care. This area contains a variety of different resources to help aid understanding of MASD, so please sign up to our events, and explore to learn more!
read more

Pain Management & Anxiety With Wound Chronicity Patients

Pain Management and anxiety intermingled in the minds of patients suffering from failed-to-heal wounds. The legendary saying is, “out of sight and out of mind.” Relating to the accuracy of the statement based on healthy, unwounded people in the world. However, in the special populations: of wound care clinics, nursing homes, and hospital facilities, anticipatory pain is a reality in the minds of patients who have experienced excruciating injuries. Fear orchestrates raw emotions associated with calamitous events’ injuries to the body (Fardin & Masumeh, 2020). Fear also creates future scenarios of horrific moments which have not happened (Fardin & Masumeh, 2020). Moreover, the anticipation of awful, painful experiences makes pain management reach a zero-improvement rate … read more

Adjunct Topical TXA Acid Shows Efficacy for Granulating Surgical Wounds

Sandra Fyfe

 

Topical tranexamic acid is an effective additional treatment for granulating wounds in Mohs micrographic surgical settings … Brianna Castillo, MD, of the University of Missouri in Columbia, and colleagues presented abstract data demonstrating the potential for adjuvant tranexamic acid (TXA) in treating granulating surgical wounds at the 2022 American College of Mohs Surgery Annual Meeting. Researchers performed a double-blind randomized controlled trial on the effectiveness of TXA in preventing bleeding in granulating surgical wounds. TXA is a drug that prevents blood clots from breaking down … “Postoperative bleeding is one of the more common complications when a wound is healing by second intent and can lead to patient distress and unnecessary return visits including possibly to emergency rooms after hours, thus generating increased cost to patients in the form of copays for emergency care,” the researchers wrote … read more

Effects of the COVID-19 pandemic on the outcome and mortality of patients with diabetic foot ulcer

The outbreak of the coronavirus disease 2019 (COVID-19) led to events that significantly impaired the treatment and management of patients with chronic diabetes. Therefore, elective treatments at hospitals were cancelled and patients with chronic ailments were instructed to stay at home and minimise the time spent in public areas. The second was due to COVID-19-induced anxiety that deterred many patients from seeking care and adhering to periodic out-patient visits. In this study, we examined the short-term effects of the COVID-19 pandemic on patients with chronic diabetes who suffered from contaminated diabetic ulcers. We conducted a retrospective study with patients who had undergone amputations following diabetic ulcers during 2019-2020. The research group included diabetic amputees during the COVID-19 outbreak period ranging from March 2020 to December 2020. The control group included diabetic amputees from the corresponding period … read more

LifeNet Health features next level wound care solutions at SAWC Spring

Events include an Innovation Theater presentation that features the science and clinical results supporting Matrion®— the first full-thickness, decellularized placental membrane — and Dermacell AWM® acellular dermal matrix

 

PHOENIX, April 7, 2022 /PRNewswire/ — LifeNet Health, the world leader in allograft biologics, is showcasing its unique allograft solutions for wounds at the 2022 Symposium on Advanced Wound Care (SAWC) Spring meeting April 7-9 in Phoenix.

 

Its featured biologic portfolio includes:

Matrion®, the first full-thickness, decellularized placental membrane for wounds, and
Dermacell AWM®, the only acellular dermal matrix clinically proven to help resolve wounds in as little as one application1.
“These solutions take wound care to the next level by helping address long-standing clinical challenges,” said Mike Falcon, Vice President of Advanced Wound Management Sales. “Thanks to LifeNet Health’s unique technologies, we are bringing clinicians the most advanced allograft biologics available to facilitate healing in their patients.”

 

Innovation Theater Breakfast Presentation
Clinicians Hayway Chiu, DPM, FACFAS, and Zakee Shabazz, DPM, FACFAS will lead an SAWC-hosted Innovation Theatre session to share their experience with Matrion and Dermacell AWM. The analysis will cover the science behind these two best-in-class therapies as well as clinical results that show how they support positive patient outcomes, using real-world case studies.

 

The session, which begins at 7:30 a.m. MST Friday, April 8, will be moderated by Valerie Marmolejo, DPM.

 

Industry-Leading Solutions
Matrion is the only biologic of its kind to fully maintain the natural thickness and structure of the placental membrane. It includes the complete trophoblast layer, which is up to four times thicker than either the amniotic or chorionic membranes2. This allows Matrion to retain up to 50 percent more native growth factors than traditional placental membranes.3 Its natural thickness also means Matrion is less likely to adhere to itself or roll up during application.4

 

Dermacell AWM is backed by more than 30 publications that demonstrate its exceptional clinical performance and ease of use. It is proven to provide complete resolution of even complex wounds, with exposed bone and tendon, in as little as one application.1

 

Both Matrion and Dermacell AWM are decellularized with LifeNet Health’s patented Matracell® technology to remove donor cells and create a biohospitable scaffold for cellular infiltration and re-vascularization.

 

About LifeNet Health
LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world’s most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

 

  1. Cazzell, S., Vayser, D., Pham H., et al. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator. Wound Repair and Regeneration. 2017.
  2. Verbruggen SW, Oyen ML, Phillips AT, Nowlan NC. Function and failure of the fetal membrane: Modelling the mechanics of the chorion and amnion. PLoS One. 2017;12(3):e0171588.
  3. LifeNet Health. TR-004-2020 Characterization of the Amnion, Chorion, and Trophoblast Layers of Decellularized and Freeze-Dried Placental membrane. 2020.
  4. LifeNet Health. ES-20-057, Placental Membrane for Wound: Design Validation. Data on File. 2020.
    SOURCE LifeNet Health

 

This article was originally published here

Evaluation of Wound Healing and Antibacterial Activities of Solvent Fractions

of 80% Methanol Leaf Extract of Brucea antidysenterica J.F. Mill (Simaroubaceae)

 

A wound is defined as damage or disruption to the normal anatomical structure and function of a living tissue. This ranges from a simple disruption in the epithelial integrity of the skin to deeper subcutaneous tissue involvement and also damage to other structures, like muscle and bone.2 Wounds can arise from physical, chemical, thermal, microbial, or immunological damage to a tissue or can be the result of a disease process like diabetes mellitus.

 

Wounds have considerable humanistic and economic burdens, both at individual and societal levels. A wound deters individual quality of life and productivity; and is associated with major economic burdens on the health care system. The current situation worldwide estimate of people with chronic wounds rises to 6 million each year. In developed countries, 1–2% of individuals in a population acquire a chronic wound during their lifetime.5 Globally, the economic burden of chronic wound is estimated to be nearly 2–4% of the health budgets.

 

Wound healing is the complex and dynamic process of restoring the structure and function of damaged tissues. It follows coordinated interactions between diverse immunological and biological systems. The interaction involves a cascade of ordered and precisely regulated steps and events, which are divided into four overlapping but distinct phases, ie, the hemostasis/coagulation phase, the inflammation phase, the proliferation phase, and the remodelling phase … read more

.

Where: San Diego Convention Center, San Diego, California, USA When: Friday, June 23, 2023 (beginning at 10:30 a.m.) through Monday, June 26, 2023 (concluding at 4:15 p.m.) conferences and events

Efficacy and Safety of Topical Solution of Diperoxochloric Acid for Neuropathic Diabetic Foot Ulcer

Results from a Phase 3, Multicentre, Randomized, Active-controlled, Parallel-group Study

 

Diabetic foot ulcer (DFU), if untreated, accounts for lower-limb amputations affecting patients’ quality-of-life. Diperoxochloric acid (DPOCL) is known to heal DFU by its antibacterial and fibroblast stimulating activity. This was a phase 3, multicentre, randomized, double-blind, active-controlled, parallel-group study conducted to evaluate the efficacy and safety of topic solution of DPOCL compared with isotonic sodium chloride solution (ISCL). Adult patients with type 1 or 2 diabetes with random blood glucose levels of <250 mg/dL, with ≤ than three full-thickness foot ulcers were enrolled. Primary efficacy endpoint was complete wound closure and secondary was wound surface area. Adverse events were analyzed as safety endpoint. Of 311 enrolled patients, 289 were randomized … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Minimizing donor-site morbidity following limbs’ injuries with keystone perforator island flap reconstruction

Timea H. Virág MD, Maximilian V. Muntean MD, PhD, Alexandru V. Georgescu MD, PhD

 

Plastic surgeons strive to choose better techniques to reconstruct the defects of the limbs, minimizing the wound healing problems, improving the aesthetic and functional outcome with less complications. This study refers to the use of keystone perforator island flap in limbs’ reconstruction, their harvesting technique to minimize donor-site morbidity, maximize the functional and cosmetic outcome, and will point on the most important indications and advantages. Between January 2014 and June 2020, a number of 28 cases were treated in our department, with simple or complex defects of the limbs. The database included patients’ demographics, comorbidities, etiology, characteristics of the flap, surgical factors, follow-up period, flap outcomes. We performed 28 keystone perforator island flaps, 14 of Type I, 12 of Type IIA, 1 of Type III, 1 of Type IV, with an average size of 69 cm2 (ranged from 1.25 cm2 to 318 cm2). Trauma was the major cause of the defects. One flap exhibited approximately 4% partial superficial necrosis. All donor sites healed without any adverse events. All patients were satisfied with the functional and aesthetic results. The keystone perforator island flaps provide a simple and effective method of wound closure by using tissues of similar texture, thickness, color. Preserving the main artery and the underlying muscle this flap reduces the donor site morbidity. The use of keystone perforator island flaps seems to be one of the most suitable choices whenever possible … read more


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Adimarket announces agreement with Alolotl Biologix

Adimarket, a subsidiary of Global Stem Cells Group, has announced an agreement with biotechnology company Alolotl Biologix to distribute biological products for regenerative medicine applications worldwide.

 

Adimarket, a subsidiary of Global Stem Cells Group (GSCG), and its subsidiary has announced an agreement with Phoenix, Arizona-based Alolotl Biologix to distribute the biotechnology company’s products for regenerative medicine applications worldwide.

 

Alolotl Biologix focuses on research to optimize the use of human biologicals and to develop biological-related products to foster regeneration and healing for a range of conditions, including orthopedic impairments, wound care, pain management, ophthalmic, cardiovascular, cosmetic, and more.

 

Adimarket will make the following amniotic liquid products available to qualified practitioners through its online store www.adimarket.net:

 

AxoBioFluid® C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
Contains extracellular matrix components for cellular attachment and proliferation
Cryopreserved for an extended shelf life
AxoBioFluid® physician benefits

 

Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy degenerated tissue is provided.
AxoBioFluid® patient benefits

 

Relevant Conditions

 

AxoBioFluidâ C Amniotic Allograft Cryopreserved Liquid, cryopreserved liquid allograft derived from the amniotic membrane that provides structural tissue to advance soft tissue repair, replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
A rich source of growth factors, proteins, cytokines, hyaluronic acid, and collagen scaffolds
Contains extracellular matrix components for cellular attachment and proliferation
Cryopreserved for an extended shelf life
AxoBioFluidâ physician benefits

 

Procedures are efficient and do not require special instrumentation.
• The use of AxoBioFluid® is billed as patient pays, which makes it a great alternative revenue source.
• A library of research papers to demonstrate efficacy is provided.
AxoBioFluid® Amniotic Allograft Cryopreserved Liquid is a cryopreserved liquid allograft derived from the placental components of the amnion to advance soft tissue repair, replacement, and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Benefits of AxoBioFluid® AxoBioFluid® is a human allograft fluid derived from the amniotic layer of the placenta. The two primary cell lines which reside in the amnion are human mesenchymal stromal cells (hMSC) and human amnion epithelial cells (hAEC). Both of these cells are considered to be pluripotent stem cells. AxoBioFluid® contains growth factors released while amniotic cells are grown in culture such as epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and transforming growth factor – beta (TGF-β). These proteins are essential for fetal growth and development and express significant therapeutic benefits when used as a treatment for various injuries and degenerative conditions. AxoBioFluid® is immuneprivileged, anti-inflammatory, anti-fibrotic, pro-vascular, and cytoprotective because of the cells being sourced from the amnion. These secreted factors also signal endogenous progenitor cells to promote regeneration and repair of damaged or degenerated tissue.

 

AxoBioFluid

 

Degenerative disorders such as osteoarthritis
• Joint pain
• Inflammatory conditions such as:
Bursitis
Tendonitis
Fasciitis
Epicondylitis
Soft tissue injuries such as:
Ligament & Tendon sprains
Muscle & Meniscus tears
Wound Care
AxoBioMembrane, a dehydrated allograft membrane patch derived from the amnion that advances wound repair, skin replacement, and reconstruction. Product details:

 

Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
Immune privileged with anti-inflammatory and anti-bacterial properties
Contains extracellular matrix components for cellular attachment and proliferation
Dehydrated and terminally e-beam sterilized for an extended shelf life.
AxoBioMembraneä Amniotic Allograft Membrane, like all allograft tissue products, has been subjected to recovery microbiological study and has been terminally sterilized with electron beam sterilization. It works by forming fibrin-elastin bonds at the wound site, ensuring excellent wound adherence. This generates a barrier that protects exposed nerve endings from irritants, providing pain relief while creating a favorable environment for tissue repair and regeneration. In addition, the AxoBioMembrane™ prevents excessive moisture loss by creating a vapor barrier at the wound surface. Growth factors present in the membrane are released into the wound bed, promoting angiogenesis leading to new blood supply needed for cellular migration, proliferation and ultimately, wound repair. Infection is one of the biggest concerns with chronic wounds. AxoBioMembrane™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate infection. It has also been reported to have anti-fibrotic properties, which can reduce scarring. The membrane contains glycoprtoteins found exclusively in the amnion. AxoBioMembrane™ lacks specific surface antigens, which make it immune-privileged and anti-inflammatory.

 

AxoBioMembraneä physician benefits

 

Procedures are efficient and do not require special instrumentation.
AxoBioMembrane™ is billed as patient pays, which makes it a great alternative revenue source.
We provide a library of research and white papers to demonstrate efficacy.
AxoBioMembraneä patient benefits:

 

Pain Reduction
Wound Adherence
Less Scarring
Faster Healing
Neovascularization
Wound Barrier
Anti-bacterial
Immune Privileged
AxoBio products are available to purchase on the Adimarket Website.

 

For more information, visit the Adimarket regenerative medicine online store website, email info@stemcellsgroup.com, or call 305-560-5337.

 

About Global Stem Cells Group

 

Global Stem Cells Group (GSCG) is a worldwide network that combines seven major medical corporations, each focused on furthering scientific and technological advancements to lead cutting-edge stem cell development, treatments, and training. The united efforts of GSCG’s affiliate companies provide medical practitioners with a one-stop hub for stem cell solutions that adhere to the highest medical standards.

 

Press Contact

 

Name: Benito Novas
Phone: +1 305 560 5337
Email: info@stemcellsgroup.com
Website: www.adimarket.net

The Miller-Newgent Amputation Scale

A comprehensive scoring system to evaluate patient-centered risk factors regarding lower extremity amputation

 

Abstract: Care of the patient with a presumed life- or limb-threatening lower extremity wound poses many challenges. The mindset regarding potential outcomes of such conditions is mostly driven by the experiences and expertise of those providing the care. This mindset generally appears as two primary actions presented to the afflicted patient: attempted resolution of the problem via medical, surgical or combination treatment, with the hope of low recurrence risk, or exacerbation and amputation—amputations at a level sufficient to, at least in the mind of the surgeon, eliminate the problem. Achieving the former outcome is dependent on a number of factors associated with both patient and caregiver. If healing is achieved, the secondary goal of prevention of recurrence may be no less arduous, with failure most likely resulting in amputation. Clearly, these considerations appear to be based more on the health professionals perception, of the patient’s physical and medical status rather than on patient-centered considerations. This article will review considerations and recommendations for lower extremity amputation, and the short- and long-term implications. Based on our research, there is clear need for a set of criteria against which to weigh not just the medical issues, but also definitive patient-centered issues when considering a lower extremity amputation. We offer a set of patient-centered, easily verified and recognized criteria that we believe addresses this need. The goal of the Miller-Newgent Amputation Scale (MENACE) is to provide a decision base from which to consider and evaluate all factors in determining the need for a lower extremity amputation. This involves identification of patient-centered issues, which are likely to produce satisfactory short- and long-term physical and quality-of-life outcomes if the amputation does proceed.

 

Declaration of interest: The authors have no conflict of interest to declare. The lead author, as a Board Certified general surgeon with 23 years’ experience in the field of advanced wound care, has been involved in the different aspects to amputation and its considerations and a common thread my colleagues and I have identified is that the expertise of those attempting to heal and salvage limbs was largely ineffectual. More often than not, the progression of high-risk conditions mandated lower extremity amputation. The progression of technology, science and products to promote healing is thought to improve limb salvage rates; however, there has not been an appreciable reduction in amputations. The thought is that those possessing the skill, knowledge and desire to promote limb salvage (which entails greater time and effort with considerably lower compensation) are few and far between. Despite advances in medical care, the rates of lower extremity amputation are unchanged at best or are even increasing.

 

Despite educational programmes touting the newest technologies for vascular intervention and advanced wound healing to mitigate those conditions commonly leading to amputation, there has been minimal change in the willingness of health professionals to consider limb salvage and indications for amputation have changed minimally. There is a clear need for a matrix against which to compare and contrast the clinical and non-clinical considerations for amputation. Since the patient is the one undergoing this potentially horrific procedure, it is only fair that all aspects of the procedure must be considered as an integral part of the decisionmaking process. The Miller-Newgent Amputation Scale (MENACE) scale was created to provide a patientcentred guide using simple, easily identified information that directly impacts on all aspects of the amputation decision process.

 

Background Considerations for the intentional removal of a body part have their roots in antiquity. Matthew 5:29–30, 18:8–9 and Mark 9:43–47 are commonly recognised biblical references to amputation. Lower extremity amputation is one of the oldest known surgical practices with Hippocrates among others providing insights.

 

In the US, 30,000–40,000 amputations are performed annually. In 2005, there were an estimated 1.6 million individuals living with the loss of a limb; by 2050, this figure is expected to rise to 3.6 million.

 

In 1954, Silbert and Hamiovici published an article recommending that lower extremity amputation be avoided, preferring more conservative surgeries such as supracondylar amputations as opposed to mid-leg amputations. In the paper they cited the Handbook on Amputations, published in 1942 by the Council on Physical Therapy of the American Medical Association, which expressed the opinion of most surgeons, when it advised the use of supracondylar amputations and warned against mid-leg amputations: an opinion justifiable at the time before the advent of antibiotics.

 

The Netherlands Society of Physical and Rehabilitation Medicine in October 2012 published its guideline on Amputation and Prosthetics of the Lower Extremities in which it recommended that the interventional radiologist, vascular internist and rehabilitation physician collectively identify and resolve those clinical issues before proceeding with a lower extremity amputation. Further, the guidelines state that treatment by a multidisciplinary team (MDT) involving a surgeon, anaesthesiologist, pain specialist, rehabilitation specialist, and possibly an internist is necessary for treatment of pain, cardiovascular risks, comorbidity and the co-determination of the level of amputation. The article identified many of the clinical indications for lower extremity amputation found in the literature; however, there is the same omission of any patient-centred, non-clinical concerns.

Table 1. Estimated change in metabolic energy expenditure based on level of amputation

Table 1. Estimated change in metabolic energy expenditure based on level of amputation

 

Reyzelman and Kim presented their idea of acceptable considerations for partial tissue removal (digital amputation) based on presenting conditions including: osteomyelitis, septic arthritis, gas gangrene, ischaemia/ gangrene and an advancing soft tissue infection. The authors concluded that early digital amputation in the appropriate patient allowed patients a return to normal activity with minimal disability.

 

Kalapatapu attempted to provide a compendium of indications for lower extremity amputation by providing an exhaustive listing of essentially all lower extremity morbidities. He stated:

 

   ‘Primary amputation may be the only option for
   patients without an anatomic option for
   revascularisation or those with medical risk factors that
   contraindicate revascularisation.’

 

Recognising that the spectrum of surgical and medical skills is considerable, and that there are an almost limitless number of non-medical factors, even attempting to define specific conditions as the basis for amputations is extremely problematic and potentially precludes the surgeon and thus the patient from any consideration of limb salvage.

 

A patient presenting with a condition prompting even the slightest consideration for lower extremity amputation likely has other issues related directly or indirectly to the presenting condition itself. It is a small leap of faith to recognise that an increase in metabolic demand places greater stress systemically on the patient with a concurrent risk of exacerbating current comorbidities as well as promoting new ones. These increased energy expenditures clearly mandate the highest scrutiny of a patient’s physical condition, both pre- and postoperatively, before undertaking any surgical consideration including lower extremity amputation. Recognising that the loss of an extremity means a dramatic change in the metabolic as well as mental status of the body, the failure to include these considerations potentially impacts on the ability of the patient to engage in activities of daily living. Estimates of the changes in metabolic energy expenditure based on the level of the amputation are shown in Table 1.

 

However, the definitive consideration must be the effect of survival from a lower extremity amputation since this takes all factors together under a single irreversible endpoint. Survival rates for individuals with dysvascular pathology undergoing major lower extremity amputations including (above the knee amputation) AKA and BKA (below the knee amputation) have been reported as 69.7% and 34.7% at 1 and 5 years, respectively.12 Mortality was found to be significantly higher for patients who underwent AKA (50.6% and 22.5% at 1 and 5 years) as compared with BKA (74.5% and 37.8% at 1 and 5 years).

 

Although amputation can be considered a failure of treatment, the actual considerations must be based on a number of factors, even when the initial impression is that salvage of the limb is untenable. There are still general categories of lower extremity conditions in which limb salvage is not appropriate. These would include traumatic limb loss or significant tissue deformation from motor vehicle or industrial accidents, malignancies whose location or dissemination precluded salvage, and congenital malformations precluding use of prosthetics or achieving a functional end result. Excluding the majority of these still leaves a considerable number of lower extremity conditions, in which the end result, amputation, unquestionably puts the patient at a higher risk of morbidity and mortality than before the decision to perform the procedure.

 

At present, the decision to recommend lower extremity amputation appears to be universally based on objective medical issues. Without recognising and attending to the equally important and pervasive, nonclinical, patient-centred issues, the decision is usually made based on the surgeon’s tunnel vision. The most basic tenet becomes that of removing the problem as the key to resolving the problem. As Ertl aptly stated:

 

‘The only contraindication for amputation is poor
health that impairs the patient’s ability to tolerate
anaesthesia and surgery. However, the diseased limb is
often at the centre of the patient’s illness, leading to a
compromised medical status. The removal of the
diseased limb is necessary to eliminate systemic toxins
and save the patient’s life.’

 

Unfortunately, the mere removal of an afflicted lower extremity under the guise of resolving the issue takes on a ‘low-hanging fruit’ mentality as it fails to address equally important patient-centred issues that often define the progress and ultimate outcome.

 

The identification of any criteria regarding the appropriateness of a lower extremity amputation based on patient-centered, non-clinical criteria has been found to be nonexistent despite an exhaustive literature search. This covered 70 years and approximately 200 citations. Brigham and Women’s Hospital in Boston uses a Pre-Amputation Assessment Checklist that, while comprehensively identifying specific patient expectations and information, does not consider any patient-centered criteria for amputation. Therefore, the Brigham tool does not recognize the potential issues and ultimate outcomes surrounding amputation. In contrast, the MENACE SCALE and its patent-centered components focus the attention on those issues related to non-clinical outcomes when lower extremity amputation is considered.

 

Table 2

The MENACE scale

It is not enough to objectively quantify only the clinical considerations for lower extremity amputation. The resulting amputation and the effect on quality-oflife must be taken into account. For that reason, there must be a combination of clinical factors together with non-clinical factors. The impact of these patientcentred, non-clinical factors cannot be overstated. The loss of all or part of a limb has a major psychological impact on the patient’s mental status. The psychological effects of amputation can be related to postoperative pain, cosmetic appearance, cultural and social effects, all potentially causing or exacerbating anxiety and depression.

 

We believe that any initial consideration for lower extremity amputation, regardless of the presenting issues, can be based on two primary factors. Those two factors are intractable pain and functionality in the presence of a potentially life- or limb-threatening condition. While these factors may at first appear to be objective they are equally dependent on the patient’s subjective impressions of their condition.

 

In considering the issues that ‘open the door’ to amputation, the authors felt that this process is analogous to ‘looking through a keyhole’ from which only a narrowed view is possible. We chose the term ‘keyhole criteria’ to represent this process as initial consideration regarding amputation. The two criteria (Table 2) establish a platform that forms the basis for the critical decision of amputation. These criteria move the decision from one that is based solely on the surgeon’s experience to a more germane one that encompasses considerations of the patient as a whole.

 

Criterion 1 is significant in that there are lower extremity conditions including neurologic, musculoskeletal or other deficits where attempted preservation would offer no benefit to the patient. When these presentations are associated with debilitating pain, then this criterion would be met and consideration for an amputation at some level would be appropriate. This criterion would require that all attempts be made to mitigate the pain. Thus, an acute presentation (following traumatic accident, postoperative complications from prosthetic implantation, etc.) would arguably require some time to be allowed to pass before accepting these criteria.

 

The issues regarding criterion 2 include preservation of the patient’s functionality and assumed morbidity and mortality of the presenting condition and that of the procedure. The goal of MENACE is to assure full consideration of all aspects of limb salvage versus amputation. Recognising that lesser procedures may provide both short- and long-term satisfactory outcomes, the issue of when to perform a lesser procedure and what that procedure may be, must be based on preservation of maximum functionality. For these reasons, attention must be directed to the patientspecific issues since information obtained provides the necessary elements required for a successful outcome. For example, the presence of distal pedal gangrenous changes in a diabetic neuropathic ulcer with a history of osteomyelitis poses a daunting problem. Not surprisingly, these findings would, in the vast majority of cases, lead to a strong recommendation for amputation. However, the usual discussion of potential complications and progression of disease state will generally lead to at least a discussion of the ‘benefits’ of simply removing the entire problem-containing lower limb. In contrast, the consideration of functionality is integral because it changes the discussion from one that obviates a potential progression of the presenting problem to one that recognises that retained maximum functionality allows ongoing quality-of-life based on retaining the limb. In simplest terms, if the extremity is still used to bear weight, provide propulsion in a wheelchair, transfer from chair to bed to commode, or even ambulate for any distance, then maintenance of that functionality takes on the highest priority. The goal becomes maximising the longevity and functionality of that extremity.

 

The authors believe that the two keyhole criteria represent a mandatory check step for medical providers who either perform or refer to those performing lower extremity amputation. These two criteria need to be used to ascertain the appropriateness of amputation for a given patient. This represents a marked departure from the practice that the decision be based on the perception of perceived benefit of amputation.

 

Initial evaluation of the patient’s presenting status with respect to the keyhole criteria should be undertaken. If the result is a decision to amputate, the MENACE scale assures that patient-centred factors are considered in the decision to amputate. Those factors placing the patient at risk for quality-of-life issues after surgery should be addressed well before amputation.

 

Table 3

The initial tool used by the authors was the 1–2 point scale to assess patient-centred factors. However, we recognised that the keyhole criteria were needed to focus the attention of the surgeon on what the authors felt were the two critical issues: pain and functionality.

 

With the focus now placed on the patient, those factors that impact on their lives both pre- and postoperatively need to be considered. While there are an infinite number of both specific and general categories to be considered, we believe that those factors identified in Table 3 represent the most salient, recognising the interrelationship of these factors and others not specifically identified.

 

The social status of the patient is integral to mental and physical wellbeing. Considerations must include: Who else is in the home? What will be the patient’s functional capacity both before and after the amputation? What is the expected effect on the family after amputation? Is the patient the primary breadwinner/caretaker for the family? Are there others who will be affected by the patient’s amputation status in the same environment (young children, teenagers, young adults, middle-agers)?

 

Habitation factors must include: where does the patient live (both geographically and in terms of the actual residence)? The geographic location, including changes in elevation (mountainous, or San Francisco hills), whether there are stairs to navigate, or consistently functioning lifts, and old versus new construction (ADA, Standards for Accessible Design related to the Americans With Disabilities Act)15 are all considerations that must be addressed before amputation.

 

Economic factors are the underpinning of what transpires with the patient and their direct family and friends. How will the patient’s economic status change after the amputation? Financial considerations are the bedrock on which much of the other issues achieve stability. Are they ready for retirement? Are they employable after amputation? Is there another breadwinner? Are they financially able to withstand loss of leg? What about the costs of treatment, prosthetics, devices? Are there accessible and available sources available to provide external financial support and can the patient access them (social security, disability insurance, etc.)? Is there adequate and sustained financial means either through a health insurance or other entity to pay for ongoing care including rehabilitation, care for any complications, medications, therapies, home health care, and if so for how long?

 

Interpersonal support and functional issues have the potential to create effects that reverberate throughout the entire recuperative period and beyond. What other intrinsic/extrinsic factors do they have to contend with? Do they live with conditions such as a small cluttered house (hoarder), ‘bad’ neighbourhood, difficulty getting to the grocery store, doctors, and social events? Is there inter-family stress such as abusive or uncaring children or relatives?

 

What psycho-emotional and self-perception issues are present? Do they already have body-centred issues (too fat, too skinny, too old, too sick …)? Is there a history of behavioural or mental health issues (depression, anxiety, obsessive compulsive disorder (OCD), schizophrenia, bipolar disorder, etc.)? How are they dealing with the potential amputation? Do they consider the recommendation for amputation a ‘death sentence’? Is there the opportunity to do something besides see the wound specialist all the time? How will they deal with the resultant disfigurement? The ultimate question is clearly: how important is that toe, foot, or leg to their life?

 

An exhaustive online search of the available literature identified definitive criteria/guidelines for removal of the gallbladder, appendix and performance of caesarean sections as well as numerous other surgeries. However, regarding amputation of a lower extremity, the overwhelming majority of articles that even entertain the rationale for performing the procedure present surgeon-based clinical considerations as the primary decision criteria and mention patient-centred factors only in passing.

 

Based on the experiences of the authors, there clearly needs to be a set of patient-centred criteria to juxtapose with the experiences of the surgeon and other providers integral to the decision-making process. We recognise that there are a myriad of compounding factors that affect provider and patient considerations that are easily overlooked and so a set of guidelines for evaluation such as the MENACE scale identifies those factors that can be easily evaluated and rectified.

 

The MENACE scale including the keyhole criteria has been used by the primary author for 23 years in one form or another. Explanation and review of the MENACE critera has been undertaken with our patients for whom amputation was the only alternative offered before coming to our clinics. In clinical practice, numerous encounters have occurred with patients marked for amputation in which their presenting condition was clearly (and ultimately) salvageable. Based on extensive clinical use, we believe that the appropriate use of this tool can balance the patient’s presentation using both the accepted medical/surgical objective criteria and the less often considered patientcentred criteria. In those situations the decision for amputation gains more credence as evaluation progresses, for those MENACE scale categories in which the highest score (2 points) is not present, appropriate actions and interventions are taken to maximise that score. For example, the patient who lives in an upperfloor apartment with an unreliable lifts should have their residence changed to one with greater accessibility even if this is to occur immediately after the surgery. The planned change allows for the full score for that category to be considered as accomplished despite its implementation postoperatively. The same holds for caregivers needed in the home following surgery. The key to MENACE is to recognise that maximising a successful outcome after the elective performance of a lower extremity amputation must be based on resolving as many patient-centred stumbling blocks as possible. We recognise that the act of doing so may not be appropriate for the surgeon themselves but believe strongly that it can be appropriately achieved by other entities including social workers, local, state and federal entities.

 

Based on our use of the MENACE scale in our own practices, we believe that a score of less than seven strongly suggests the highest potential for postoperative issues that will have an impact on the patient’s shortand long-term recovery and status. The failure to address identified issues both individually and collectively in the preoperative/perioperative periods may preclude a safe and complication-free recovery. MENACE was created to fill an unmet need. We understand that MENACE will require ‘real-life’ testing and validation. It is our expectation that when used alongside other criteria, it will provide a basis for expansion, revision, confirmation or deletion of the considerations we have proposed when a lower extremity amputation is considered.

 

Conclusion

The recommendation for, and performance of, a lower extremity amputation appears to be based primarily on criteria that remain undefined despite advances in all aspects of medicine. Although certain lower extremity presentations preclude safe attempts at limb salvage, there is clearly a trend towards performance based more on subjective criteria of the attending health-care providers than on clear objective patient-based criteria.

 

Lower extremity amputation does not merely remove all or part of the lower extremity. The interdependence of structure and function, both before and after amputation, and the potentially catastrophic consequences of failing to consider these factors, mandates that there be a specific and definitive categorical assessment of patient-centred factors rather than the current criteria, which are based solely on the skill, education and experience of the medical providers. When these decisions are based solely on their own criteria rather than those of the patient—who represents the primary consideration regarding a successful outcome—then failure to identity and resolve potential patient-centred issues means that the patient is not truly the focus of the intended procedure, although they will suffer any untoward effects. The loss of a lower extremity does not merely mean that a pending problem has been resolved but that the potential loss of the limb now presents its own life-affecting challenges well beyond the time that the surgical incision heals.

 

References
1 Quality Improvements Organization. Strategies to Help Reduce
Diabetes-Related Lower Extremity Amputations Among Minority
Populations. April 2017, https://tinyurl.com/yd3hcgrn (accessed 7
September 2017)
2 Murdoch G, Bennett-Wilson A Jr, Amputation: Surgical Practice and
Patient Management. Butterworth-Heinemann Medical, 1996.
3 Tooms RE. Amputations. In: Crenshaw AH (ed). Campbell’s Operative
Orthopedics (7th edn) Mosby-Year Book,1987: 597–637
4 Ertl JP. Amputations of the lower extremity. Medscape. 2016. http://bit.
ly/2uUFuEv (accessed 14 August 2011)
5 Zeigler-Graham K, Mackenzie EJ, Ephraim PL et al. Estimating the
prevalence of limb loss in the United States: 2005 to 2050. Arch Phys
Med Rehabil 2008; 89(3): 422-429. https://doi.org/10.1016/j.
apmr.2007.11.005
6 Silbert S., Haimovici H. Criteria for the selection of the level of
amputation for ischemic gangrene. JAMA 1954; 155(18): 1554–1558.
https://doi.org/10.1001/jama.1954
7 Book Notices: Handbook on Amputations JAMA 1942; 120(9):724.
https://doi.org/10.1001/jama.1942.02830440066028
8 Netherlands Society of Physical and Rehabilitation Medicine
(Nederlandse Vereniging van Revalidatieartsen – VRA). Guideline: amputation and prosthetics of the lower extremities. Utrect. 2012. http://bit.ly/2uCbGRM
9 Reyzelman A, Kim J. A guide to digital amputations in patients with
diabetes. Podiatry Today. 2011; 24(9). http://bit.ly/2wX6Ew2 (accessed 14
August 2011)
10 Kalapataku V. Lower extremity amputations. UpToDate. 2017. http://
www.uptodate.com/contents/lower-extremity-amputation (accessed 14
August 2017)
11 Karadsheh M. Amputations. Orthobullets.com. 2017. http://www.
orthobullets.com/trauma/1052/amputations (accessed 14 August 2017)
12 Brigham And Women’s Hospital Department of Rehabilitation
Services. Physical therapy standard of care: lower extremity amputation.
2011. http://bit.ly/2vwFFct (accessed 14 August 2011)
13 Hakami, K. Pre-operative rehabilitation evaluation of the dysvascular
patient prior to amputation. Phys Med Rehabil Clin N Am. 2009; 20(4):
677-688. https://doi.org/10.1016/j.pmr.2009.06.015
14 Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to amputation:
recognition and treatment. Prim Care Companion J Clin Psychiatry 2007;
9(4): 303–308
15 ADA. Information and technical assistance. standards for accessible
design related to the Americans With Disabilities

Lakewood-Amedex Prepares To Launch A Phase 2 cDFU

     Clinical Trial for Its Nu-3 Antimicrobial In The Bahamas

 

SARASOTA, Fla.Jan. 17, 2019 /PRNewswire/ — Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection and promote wound healing in patients with chronic diabetic foot ulcers (cDFU).   The trial will be under the direction of the prominent Bahamian surgeon, Dr. Daniel Johnson, who is the principal and chief researcher of Foot and Ankle International (Bahamas). He is an acknowledged expert on the treatment of diabetic foot ulcers.

 

Nu-3, which belongs to a proprietary class of antimicrobials called Bisphosphocins™, was first used as a solution to treat infected diabetic foot ulcers for seven days in a Phase 1/2 a clinical trial completed late 2017, when it was well-tolerated with no reported adverse events related to treatment. Results showed promising trends with median wound area reduction (change from baseline) of 65.5% in the 2% Nu-3 treatment arm, versus 29.9% in the placebo arm.

 

Lakewood-Amedex, based in Sarasota, Florida, has developed a proprietary gel formulation of Nu-3, said they intend to conduct a Phase 2 clinical trial commencing early 2019 using this compound to treat chronic diabetic foot ulcers (cDFU), with a 28-day treatment period using escalating concentrations of Nu-3.  The company believes this longer treatment with increased Nu-3 concentration will improve the potential to reach a point of healing or partial healing of the patient’s ulcers.  Lake-Amedex also intends to conduct an ‘adaptive arm’ of this clinical trial which will involve treating an increased number of patients with the most effective concentration of the gel formulation to achieve robust clinical data.

 

Steve Parkinson, President and CEO of Lakewood-Amedex, said the company will seek to recruit up to 120 patients for the entire clinical trial and has identified the Bahamas as not only an up and coming location for medical specialty in DFU in the treatment of diabetic foot wounds and ulcers, but also a potential source of large numbers of patients … read more

KMT Medical Announces Ownership of US-Based Twenty Second

Company and ABC Medical Holdings, Inc.

 

TAMPA, Fla.Sept. 14, 2018 /PRNewswire/ — KMT Medical Incorporated (KMT Medical), an international group of companies providing healthcare services to consumers, announces its ownership of the US-based holding company, Twenty Second Company and its operating subsidiary ABC Medical Holdings, Inc (ABC Medical). These companies will join their European Service Business counterparts, operating under KMT Medical.

 

ABC Medical is one of the nation’s leading and fastest growing homecare companies for urology. The ABC Medical team is the leading provider in the industry committed to adaptive sports sponsoring over 100 events annually. ABC Medical also provides ostomy, incontinence and wound care services. This company operates under the philosophy of providing legendary customer service and honoring clinical and patient choice.

 

Announced in 2017, KMT Medical is a wholly owned subsidiary of The Firm of John Dickinson Schneider Inc. (JDS Inc). “KMT Medical companies share the same patient-focused mission of the parent company,” says V. George Maliekel, President and Chief Executive Officer of JDS Inc, “to make life more rewarding and dignified for people who use our products and services, and the same vision, to grow and prosper as an independent company and in the process to become better human beings.” These companies operate under and adhere to a set of policies that include respecting clinical decisions, honoring patient choice in matters of product selection, and collaborating with payers and suppliers to provide high quality products and personalized services to consumers.

Full press release at Cision

Treating Diabetes with GLP-1 Reduces Heart Disease, Fewer Foot Ulcers

Two analyses from the LEADER Trial show reduced risks of deaths and better outcomes in both heart health and diabetes-related foot ulcers and associated complications in patients with type 2 diabetes who are at increased risk for cardiovascular disease … GLP-1 Proves Effective in Lessening Risks of 2 Common Diabetes-Related Risks … Patients with type 2 diabetes who were at heightened risk of cardiovascular disease (CVD) and received liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1) saw a reduction in CVD events and cardiovascular death … read more

AmpliPhi Biosciences Announces Updated Positive Clinical Results

     for its Expanded Access Program

 

  • 21 patients at 7 hospitals, with serious or life-threatening infections not responding to antibiotics, have now been treated with AB-SA01 (targeting S. aureus) or AB-PA01 (targeting P. aeruginosa) under AmpliPhi’s expanded access program
  • Over 1,000 doses of bacteriophage product candidates, AB-SA01 or AB-PA01, have been administered as part of the expanded access program since mid-2017 and have been generally well tolerated, with no serious adverse events attributable to bacteriophage treatment
  • 84% of patients achieved treatment success at the end of therapy

 

AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced updated topline clinical results for its ongoing single-patient expanded access program. 84% of patients achieved treatment success (physician’s assessment) at the end of therapy, defined as complete resolution or significant improvement of baseline signs and symptoms.

 

AmpliPhi has now provided its investigational bacteriophage therapeutics for a total of 21 patients, at 7 hospitals, with serious or life-threatening infections not responding to antibiotic therapy. These patients were treated with AB-SA01 or AB-PA01 under single-patient expanded access programs in the U.S. (Emergency INDs per the U.S. Food and Drug Administration) or Australia (Special Access Scheme per the Australian Therapeutic Goods Administration). The following analysis updates the data previously announced by the company on January 3, 2018 … read more

The role of bacteria and biofilms in non-healing wounds

Broadcast times available: 8:00 AM (UK), 11:00 AM (UK), 15:00 PM (UK)

 

Evidence has proven the positive effects of topical oxygen therapy on chronic, hard-to-heal wounds. It is becoming widely accepted that hard-to-heal wounds contain biofilm and that the presence of biofilm delays and/or prevents healing. This webcast will inform practitioners about the issue of biofilm and how it affects wound chronicity, as well as how topical oxygen therapy may help to kickstart stalled healing. The NATROX study has shown that topical oxygen therapy has a positive effect on biofilm in chronic wounds, and this webcast will provide practical guidance so this can be applied in practice to improve healing outcomes ….. read more

Liraglutide Lowers Risk for Amputation in Patients with Type 2 Diabetes and CV Risk

Liraglutide lowers risk for amputation: investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.

 

The word may still be out on whether certain oral diabetes medications puts patients at risk for lower limb complications, but a new study has shown that liraglutide is not one of them. A post hoc review analysis of the LEADER trial published in Diabetes Care examined the effects of Liraglutide on rates of foot ulceration and amputation in patients at high risk for cardiovascular (CV) events.

 

Liraglutide, a GLP-1 agonist, is an injectable glucose-lowering medication used in patients with type 2 diabetes. GLP-1 agonists act by mimicking the effects of the hormone GLP-1, which increases insulin secretion and lowers glucagon release. This, in effect, causes increased satiety and slowed gastric emptying, with one of the main benefits of GLP-1 agonists being weight loss in patients with diabetes … read more

Study: Antiobitics, probiotics together eradicate bacteria that infect wounds

By combining antibiotics and probiotics, researchers have developed a one-two punch to eradicate two strains of drug-resistant bacteria that often infect wounds, according to a preclinical study … MIT researchers encapsulated probiotic bacteria in a protective shell of alginate, which is a biocompatible material that prevents the probiotics from being killed by the antibiotic. The findings were published Wednesday in the journal Advanced Materials … Probiotics, which are good live bacteria and yeasts, help send food through the digestive system by affecting nerves that control gut movement. Probiotics come from supplements, as well as foods that are prepared by bacterial fermentation, including yogurt, kefir, sauerkraut, tempeh and kimchi … read more

related: Probiotics and antibiotics create a killer combination

Experimental Stem Cell Therapy Speeds Up Wound Healing in Diabetes

The healing of wounded skin in diabetes can be sped up by more than 50 percent using injections of stem cells taken from bone marrow, a new study in mice shows.

 

The research, led by scientists at NYU School of Medicine, focused on a chain of events in diabetes that makes skin sores more likely to form and less likely to heal.

 

Namely, the body’s failure in diabetes to break down dietary sugar creates molecules called free radicals that can wreak havoc on cells and damage their DNA. These free radicals also trigger an inrush of immune cells and chemicals meant to fight infection that, researchers say, instead kill normal cells and cause diabetic skin ulcers. These wounds, they note, can take twice as long to heal as in healthy mammals and are prone to infection.

 

Published in the January issue of the journal Diabetes, the study showed that the injected stem cells restore a cell signaling pathway called Nrf2/Keap1, recently shown by the NYU team to be disrupted in diabetes. The rebalancing brought on by stem cell therapy, the researchers say, decreased wound healing time to 21 days in treated diabetic mice compared with 32 days in untreated diabetic mice. By contrast, normal mouse skin wounds usually heal in 14 days.

 

“Our study shows that in mice, stem-cell-based therapies can stimulate the Nrf2/Keap1 pathway to counteract … read more

HMP Announces Multiple Endorsements for SAWC Spring

HMP, a leader in healthcare events and education, today announced that its annual Symposium on Advanced Wound Care (SAWC) Spring, taking place in San Antonio, Texas, May 7-11, 2019, and serving as the annual meeting of the Wound Healing Society (WHS), has received endorsements from the following prominent organizations:

  • American Physical Therapy Association’s Academy of Clinical Electrophysiology and Wound Management:

“The Wound Management Special Interest Group of the American Physical Therapy Association’s Academy of Clinical Electrophysiology and Wound Management endorses the Symposium on Advanced Wound Care,” says Melissa Johnson, Chair, Wound Management Special Interest Group. “SAWC promotes interdisciplinary wound management and provides robust continuing education for physical therapists and other healthcare providers enabling optimal care for patients with wounds.”

  • Critical Limb Ischemia (CLI) Global Society, the only organization solely dedicated to patients and the public health aspect of CLI:

“The Critical Limb Ischemia Global Society is endorsing the Symposium on Advanced Wound Care, an important conference that brings together the latest technologies, best practices, and research in all areas of wound care,” says founding board member, Jihad A. Mustapha, MD. “In our efforts to further share information and educate practitioners, we are especially proud to take part in this year’s Spring meeting by organizing a session on CLI awareness, diagnosis, and treatment.”

  • National Pressure Ulcer Advisory Panel (NPUAP), the nation’s leading scientific expert group on pressure injury prevention and treatment, is endorsing and organizing three sessions at the meeting:

“The National Pressure Ulcer Advisory Panel is proud to endorse and support the Symposium on Advanced Wound Care, an important medical conference for those of us who rely on the latest technologies to remain up to date on wound care and prevention,” says Dr. Nancy Munoz, DCN, MHA, FAND, Assistant Chief, Nutrition and Food Services, Southern Nevada VA System. “As part of our support and engagement, we are delighted to present three sessions during this conference, sharing expertise and best practices in areas of pressure injury prevention and treatment.”

  • American Venous Forum (AVF), which fosters cutting-edge research and clinical innovation and educates healthcare professionals, patients, and policy makers about venous and lymphatic diseases, is endorsing SAWC Spring and coordinating a session at the meeting:

“The American Venous Forum proudly supports the Symposium on Advanced Wound Care and its role in furthering education, particularly in the areas of venous and lymphatic disease,” says William Marston, MD, Professor of Surgery University of North Carolina; and Secretary of the Board of Directors of the American Venous Forum. “The cutting-edge topics and emerging therapies presented at this meeting are important as we all continue to strive for improvements in the prevention and treatment of patients with chronic nonhealing wounds.” … read more

Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes

Patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation, according to a study recently published in Diabetes Care.

 

Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. Patients in the LEADER study were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was specified as a medical event of special interest, and all complications related to the ulcer were documented.

read more

Diabetic Limb Salvage Conference

Highly regarded as one of the world’s finest limb salvage events, MedStar Georgetown University Hospital’s DLS conference brings together the most eminent lower limb specialists for an unforgettable meeting. It is a multidisciplinary team approach meeting that provides each member of the healthcare team with the education and resources needed to heal wounds and prevent amputations. It features a prominent international faculty that promotes the importance of a multispecialty approach in limb salvage. The course highlights evidence-based approach with emphasis on take-home points, techniques, and functional outcomes ….  read more

Durable Healing Outcomes of Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading International Clinical Conferences

OCEANSIDE, Calif., Aug. 26, 2021 /PRNewswire/ — Advanced Oxygen Therapy Inc. (AOTI) announced today that its unique multimodality Topical Wound Oxygen (TWO2) therapy was recently highlighted at multiple leading international clinical conferences across the United States and United Kingdom. AOTI participated both as a sponsor and exhibitor at these events that were conducted in a hybrid format, where attendance could be either in person, or virtually, to allow for the greatest clinician engagement, something that has now become standard during the ongoing COVID-19 pandemic.

 

Clinical Societies
Clinical Societies
The prestigious Malvern Diabetic Foot Conference, the world’s longest standing international multidisciplinary diabetic foot meeting, was held in Malvern, UK, from July 7 – 9, where during the New Treatments for Diabetic Foot Lesions session, the growing portfolio of high quality clinical evidence supporting the effectiveness of cyclical-pressure TWO2 therapy in healing DFU, was expertly summarized by Professor Robert Frykberg, DPM, MPH., who also presented the results from the recently published paper entitled: Topical oxygen therapy for diabetes-related foot ulcers: A systematic review and meta-analysis, by Professor Golledge et al., which further highlighted the strength of the TWO2 RCT.

 

The Annual Scientific Meeting (The National) of the American Podiatric Medical Association was held in Denver, USA from July 29 – August 1, where a breakthrough abstract by Matthew G. Garoufalis, DPM and Aliza M. Lee, DPM, MS, entitled: The Power of TWO2: Real World Evidence of the Long-Term Healing and Health Benefits of Cyclical Pressurized Topical Wound Oxygen Therapy in Diabetic Foot Ulcerations was presented, further demonstrating significant reductions in Hospitalization and Amputations over 12-months for DFU patients treated with TWO2, compared to those who were not.

 

The 2021 Vascular Annual Meeting of the Society for Vascular Surgery was held in San Diego, USA from August 18 – 21, where during a Vascular Live Presentation, entitled: TWO2 Therapy for Healing DFU and VLU: Reducing Hospitalizations and Amputations, the eminent vascular surgeon, Anil Hingorani, MD, summarized the cyclical oxygen pressure noncontact compression mechanism of action of TWO2, reviewed real word cases and even provided a video testimonial from a patient who had suffered with nonhealing Venous Leg Ulcers (VLU) for years, until finally healing with the addition of TWO2 therapy.

 

Dr. Mike Griffiths, CEO and Medical Director of AOTI, commented; “AOTI is proud to continue to support the world’s leading clinical societies and wound care physicians in their quest for more durable healing of Diabetic Foot Ulcers and Venous Leg Ulcers by utilizing our unique multimodality approach. Our evidence-based TWO2 therapy is applied by the patient safely at home, which when combined with our enhanced Telehealth features, helps clinicians maintain critical continuity-of-care during the ongoing COVID-19 pandemic. It is especially rewarding to hear in a patient’s own words the significant impact that durably healing their refractory wounds has on their daily lives. It’s both quite humbling and motivating for us all to continue in our cause to make TWO2 therapy available to all who could benefit from its life altering outcomes.”

 

About AOTI

AOTI is a privately-owned company based in Oceanside, California USA and Galway, Ireland that provides innovative solutions to resolve severe and chronic wounds worldwide. Our products reduce healthcare costs and improve the quality of life for patients with these debilitating illnesses. Our patented non-invasive Topical Wound Oxygen (TWO2) therapy is unsurpassed in closing all chronic wound types.

 

For more information see: www.aotinc.net

Contact:
Dr. Mike Griffiths
CEO and Medical Director
317543@email4pr.com
(760) 672 1920

SOURCE AOTI Inc.

The ISWCAP and ASEAN wound conference 2021

The ISWCAP and ASEAN wound conference was held online on the 19–20 June 2021. Over the two-day programme the 434 participants saw 22 lectures and plenary sessions along with sponsored lunch symposia.

The chair of the organising committee Prof. Dr. Harikrishna K.R.Nair gave the opening address for what he described as “An inspiring two days, with a wealth of knowledge shared among the wound care family”. There were updates from Gulnaz Tariq on the World Union of Wound Healing Societies (WUWHS) events and Karen Ousey on behalf of the International Wound Infection Institute (IWII), along with sessions on diabetic foot ulcers, amputation, surgical site infection, oxygen therapy and much more. It was a truly international event with both speakers and delegates from Europe, North America, South America mainly Brazil, South Africa and Asia.

Recordings of that day will be uploaded onto the Malaysian Society Of Wound Care Professionals (MSWCP) website www.mswcp.org

Principles of Wound Healing

A wound is a break in the continuity of a bodily tissue, such as the skin or mucous membrane. Wounds can be caused by events that are external to the organism – such as trauma, burns, or surgical incisions; and wounds can also be of endogenous origin – such as a distal ischemic event involving the toes due to embolism or arterial stenosis … Wound attributes, such as its causative mechanism, size, depth and location are useful for characterizing its type. When a wound is being assessed, it is also important to determine the stage of wound healing, extent of tissue repair, presence of any obvious elements preventing complete wound closure, and the patient’s psychological status. Complete restoration of tissue integrity requires multidisciplinary care and patient adherence to the recommended treatment …The patient’s baseline clinical condition greatly influences the wound healing process. Healthy individuals tend to recover quickly, with restoration of skin integrity and scars that have a better appearance as well as fewer complications. Patients with chronic diseases (e.g. diabetes mellitus and hypertension, malnutrition or obesity) tend to present delayed wound healing and have greater risk of complications such as infection, and functional and psychological sequelae … read more

Visceral Fat Associated With Increased Arterial Stiffness in Youth With Obesity

Data show In youth with obesity, but not healthy weight, visceral fat was positively associated with PWV and was predictive of PWV beyond BMI and waist circumference.

New research dove into associations between visceral fat and arterial stiffness in youth with healthy weight, obesity, and type 2 diabetes (T2D), in order to discover whether the relationships were independent of body fatness estimates as a predictor of cardiovascular events read more

SKIN BACTERIA CAN HELP WOUNDS TO HEAL

Skin wounds heal by coordinated induction of inflammation and tissue repair, but the initiating events are poorly defined. Here we uncover a fundamental role of commensal skin microbiota in this process and show that it is mediated by the recruitment and the activation of type I interferon (IFN)-producing plasmacytoid DC (pDC). Commensal bacteria colonizing skin wounds trigger activation of neutrophils to express the chemokine CXCL10, which recruits pDC and acts as an antimicrobial protein to kill exposed microbiota, leading to the formation of CXCL10–bacterial DNA complexes … read more

Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes

Patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation, according to a study recently published in Diabetes Care.

Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. Patients in the LEADER study were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was … read more

Privacy Policy

…of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and

Interpretable Machine Learning for the Prediction of Amputation Risk Following

Lower Extremity Infrainguinal Endovascular Interventions for Peripheral Arterial Disease

 

Abstract
Purpose: Severe peripheral artery disease (PAD) may result in lower extremity amputation or require multiple procedures to achieve limb salvage. Current prediction models for major amputation risk have had limited performance at the individual level. We developed an interpretable machine learning model that will allow clinicians to identify patients at risk of amputation and optimize treatment decisions for PAD patients.

 

Methods: We utilized the American College of Surgeons National Surgical Quality Improvement Program database to collect preoperative clinical and laboratory information on 14,444 patients who underwent lower extremity endovascular procedures for PAD from 2011 to 2018. Using data from 2011 to 2017 for training and data from 2018 for testing, we developed a machine learning model to predict 30 day amputation in this patient population. We present performance metrics overall and stratified by race, sex, and age. We also demonstrate model interpretability using Gini importance and SHapley Additive exPlanations.

 

Results: A random forest machine learning model achieved an area under the receiver-operator curve (AU-ROC) of 0.81. The most important features of the model were elective surgery designation, claudication, open wound/wound infection, white blood cell count, and albumin. The model performed equally well on white and non-white patients (Delong p-value = 0.189), males and females (Delong p-value = 0.572), and patients under age 65 and patients age 65 and older (Delong p-value = 0.704).

 

Conclusion: We present a machine learning model that predicts 30 day major amputation events in PAD patients undergoing lower extremity endovascular procedures. This model can optimize clinical decision-making for patients with PAD.

 

Keywords: Endovascular intervention; Machine learning; Peripheral artery disease; Risk assessment.

from PubMed


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Ankle-Brachial Index Is Independently Associated With Cardiovascular Outcomes

and Foot Ulcers in Asian Patients With Type 2 Diabetes Mellitus

BACKGROUND AND AIMS: The ankle-brachial index (ABI) is an efficient tool for objectively documenting the presence of lower-extremity peripheral arterial disease (PAD). The predictive factors of cardiovascular events and diabetic foot ulcer were not clear from the ABI examination in Taiwanese patients with type 2 diabetes mellitus (DM).

METHODS: We enrolled 482 patients with type 2 DM who regularly visited the outpatient department of Chang Gung Memorial Hospital and received ABI as well as brachial-ankle pulse wave velocity … read more

Frailty Is a Risk Factor for Poor Diabetic Foot Ulcer Healing and Re-hospitalisation

The prevalence of frailty was higher in patients hospitalised with diabetic foot ulcers (DFUs) and was associated with poor wound healing and re-hospitalisation events … A better understanding of frailty may help guide individualised care planning for patients with DFUs … A prospective cohort study included 76 patients with DFUs (type 1 diabetes, n = 8; type 2 diabetes, n = 68) admitted to St Thomas’ Hospital, London … read more

Antimicrobial Stewardship In Wound Care

Antimicrobial resistance (AMR) is now one of the leading causes of death around the world. The World Health Organization (WHO) has declared that AMR is one of the top 10 global public health threats facing humanity. The inappropriate use of antimicrobial drugs contributes to AMR and adverse events, and improving antimicrobial prescribing practices is a patient safety priority.[5] In 2013, the Centers for Disease Control and Prevention (CDC) estimated that at least 2 million illnesses and 23,000 deaths per year were caused by antibiotic-resistant bacteria in the United States. A more recent study estimated that in 2019, 44,800 deaths were directly caused by AMR and 186,000 deaths were associated with AMR in North America … By default, chronic wounds are contaminated by several types of bacteria. When the host (patient) does not adequately respond to bacterial contamination, this contamination can turn into colonization, which can further turn into infection. Wound infections are often caused by bacteria that are becoming increasingly resistant to common antibiotics due to antibiotics misuse and/or overuse.[2][3] It is thus imperative that antibiotic prescribing practices evolve such that antibiotics are prescribed only when they are essential … read more

RevitaDerm Wound Care Gel Recalled Over Bacterial Contamination, FDA Warns

Double-check your medicine cabinet: One lot of RevitaDerm, a wound care gel, is being recalled due to bacterial contamination, per a notice posted by the Food and Drug Administration (FDA).

Blaine Labs triggered the voluntary recall after testing revealed that one bottle of RevitaDerm contained Bacillus cereus, a bacteria that could lead to “life-threatening, invasive infections,” per the FDA. No adverse events related to this recall have been reported yet … read more

Maceration Mitigation: Recognition, Prevention, and Management of Overhydrated Wounds

Maceration is a common clinical complication that poses challenges in chronic wound treatment.1 Excessive moisture can be trapped on the wound surface, especially when occlusive dressings are overused or when nonbreathable cover dressings are applied for extended periods. Maceration as part of the broader umbrella of moisture-associated skin damage (MASD) occurs as a cascade of events that stem from an impaired microclimate and increased humidity on the wound’s surface. The increased moisture level causes overhydration and the stratum corneum to swell, resulting in decreased tensile strength of this epidermal layer … read more

Intensive glycemic control may prevent diabetic foot ulcers

medwireNews: Early intensive glycemic control may reduce the long-term risk for foot ulcers in people with type 1 diabetes, suggest data from the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) study … The DCCT included 1408 people with type 1 diabetes who completed an average of 6.5 years of intensive (target glycated hemoglobin [HbA1c] <6.05% [42.6 mmol/mol]) or conventional (no specific glycemic target) diabetes treatment and subsequently underwent 23 years of follow-up in the EDIC study … During this period, 195 participants developed at least one diabetic foot ulcer (48 people had multiple events) and 36 needed lower extremity amputation … read more

Maceration Mitigation: Recognition, Prevention, and Management of Overhydrated Wounds

Maceration is a common clinical complication that poses challenges in chronic wound treatment.1 Excessive moisture can be trapped on the wound surface, especially when occlusive dressings are overused or when nonbreathable cover dressings are applied for extended periods. Maceration as part of the broader umbrella of moisture-associated skin damage (MASD) occurs as a cascade of events that stem from an impaired microclimate and … read more


LinkedIn:
Alex M. Aningalan
WoundSource

Retrospective Analysis Using Viable Placental Membrane Allografts in Chronic Wounds

Introduction. Viable placental membrane (vPM) has been shown to decrease time to healing, adverse wound events, and wound-related infections. Wound research exclusion criteria commonly exclude wound types other than diabetic foot ulcers and venous leg ulcers (VLUs), comorbidities including peripheral arterial disease (PAD) and uncontrolled diabetes mellitus (DM), and wounds with exposed bone or tendon. Objective. This retrospective research study evaluated the clinical use and outcomes of the vPM with living mesenchymal stem cells used in chronic wound management in the community hospital outpatient department setting with the goal of comparing real-world use and outcomes of the product with use and outcomes described in the chronic wound literature … read more

Wound Care Startup Could Reduce Home Health Time

A biomedical engineer and a health care entrepreneur have teamed up to improve wound care with a product designed to prevent infection and reduce the need for some post-acute care, including home health.

 

FM Wound Care, LLC, based in Trenary, Michigan, is awaiting U.S. Food and Drug Administration approval on a nitric-oxide-infused, self-sterilizing wound dressing designed to kill bacteria following surgery. The post-op bandage could potentially reduce the need for some care performed by home health care providers, and lower overall wound care costs.

 

Megan C. Frost, PhD, and entrepreneur Jeff Millin believe their product—the Sentry Wound Dressing—prevents infections by slowly releasing nitric oxide (N.O.) over the course of seven days, allowing patients to wear the same wound dressing for a week.

 

“If a nurse has to change a dressing, that takes quite a bit of time,” Millin explained to Home Health Care News. “If you only had to do that once every seven days as opposed to once every other day, the savings could be significant.”

read more

 

Wound Care Clinical Trials: Setting the Record Straight

A recent article by Kaiser Health News misquoted me as saying that we enroll only “healthy” patients in our clinical trials. At moments like this, one feels that something has been overlooked. One of my research coordinators, recalling the serious adverse events (SAEs) of the previous week said, “The only patients sicker than ours are underground.”

 

Anyone who has ever spent more than ten minutes in a wound clinic knows that our patients are anything but healthy. Our acuity levels mirror the dialysis and transplant units. We check the obituaries when our patients miss appointments.

The Chronic Wound Epidemic

Although it should be, this is not just a minor annoyance. A procession of anecdotal observations on the failing health of the wound care space—in a time of flux and disarray—is neither enlightening nor supportive. The article itself focuses on the use of expensive products in wound care. In comparison to other medical specialties, such as oncology or cardiology, our products are inexpensive and cost effective. Chronic wounds are an unacknowledged epidemic. The huge increase in spending has less to do with the cost of wound care products than it does to the staggering number of patients who need them. Why is wound care research so poorly funded? The National Institutes of Health (NIH) does not even have a wound care division … read more

The Save A Leg, Save A Life Foundation was incorporated as a new non-profit organization in the State of Florida during May of 2015. We are poised and excited to make an impact on reducing the number of amputations. We will shape and build SALSAL to achieve its goals and to make Save A Leg, Save A Life into a universally recognized phrase and concept, one that resonates and “connects the dots” between non-healing wounds, Peripheral Arterial Disease and Amputations, as well as catastrophic events such as heart attack and stroke … website

Docs In Socks

Self-sealing miniature ‘wound’ created by engineers

Biomedical engineers have developed a miniature self-sealing model system for studying bleeding and the clotting of wounds. The researchers envision the device as a drug discovery platform and potential diagnostic tool.

 

A description of the system, and representative movies, were published Tuesday online by Nature Communications.

 

Lead author Wilbur Lam, MD, PhD says that blood clotting involves the damaged blood vessel, platelets, blood clotting proteins that form a net-like mesh, and the flow of the blood itself.

 

“Current methods to study blood clotting require isolation of each of these components, which prevents us from seeing the big picture of what’s going with the patient’s blood clotting system,” says Lam, assistant professor in the Department of Pediatrics at Emory University School of Medicine and in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University read more

Screenshot from video showing blood cells streaming through a “wound” and a clot forming. The red-stained cells are actually white blood cells. A green extracellular glue can be seen at the top of the wound; this is fibrin, which holds the clot together. See the full video at: https://youtu.be/l7k1dGfKG0g

Inflammation in Chronic Wounds

Non-healing chronic wounds present a major biological, psychological, social, and financial burden on both individual patients and the broader health system. Pathologically extensive inflammation plays a major role in the disruption of the normal healing cascade. The causes of chronic wounds (venous, arterial, pressure, and diabetic ulcers) can be examined through a juxtaposition of normal healing and the rogue inflammatory response created by the common components within chronic wounds (ageing, hypoxia, ischaemia-reperfusion injury, and bacterial colonisation). Wound bed care through debridement, dressings, and antibiotics currently form the basic mode of treatment. Despite recent setbacks, pharmaceutical adjuncts form an interesting area of research.

 

The skin forms an important and effective barrier against the environment. It plays a vital role in protection against insults such as bacteria, xenobiotics and dehydration. When a cutaneous injury occurs, the body initiates a series of complex events to re-establish this protection. Wound healing can be roughly divided into four continuous and overlapping phases: (1) haemostasis; (2) an immediate inflammatory response defined by an infiltration of cytokine-releasing leukocytes with antimicrobial functions; (3) these cytokines kick off a proliferative phase where new epithelium, blood vessels, and extracellular matrix (ECM) are laid down; (4) over a period of weeks to months, the wound contracts as the ECM is remodelled []. These highly regulated cellular, humoral and molecular processes have been described as an orchestral performance—a potential flawless interplay can lead to perfect regeneration; however, human adult wounds undergo a repair process that leads to scarring, and, in some cases, non-healing chronic wounds ….  read more

TIME to face the challenge of wound infection

Complex wounds, Events, Infection | Schulke
TIME to face the challenge of wound infection.
This microsite follows on from the plenary session,
chaired by Kath Vowden at the Wounds UK conference, Harrogate 2016.

Click here to view the microsite

Living with a Diabetic Foot Ulcer

Patient Perspective:
An Interview with Robert S. Meyer by Janet L. Kuhnke Robert Meyer lives with diabetes and a foot ulcer. He has attended multiple Wounds Canada events as both a speaker and to learn more about how he can manage his condition, heal his wound and prevent further foot complications. He is interviewed here by wound care clinician and educator Janet Kuhnke.

 

Janet L. Kuhnke: Robert, you attended the fall 2017 Wounds Canada conference in Mississauga, Ontario. Can you tell me what this was like for you as a patient?

 

Robert S. Meyer: I was there as a patient and a speaker, but it was not until I got back home that the depth of my message sank in. First, I wanted to do my talk as a tribute to my mother, who had a nasty death due to the complications of diabetes. Second, if my message could help someone, it would be worth it all. Not just for other patients but for other service providers who need to find their own inner voice and become advocates for themselves or others, no matter the issue. Third, telling my story has a profound impact on my own healing journey. Now I know why victims of trauma need to tell their story as part of their healing. The important part is knowing that someone has listened and heard … read more

Prevention of Plantar Ulcers in People With Diabetic Peripheral Neuropathy

Using Pressure-Sensing Shoe Insoles

 

The SurroSense Rx system is a set of pressure-sensing shoe insoles that connect wirelessly to a proprietary smartwatch and is intended for people with diabetes who have mild to moderate sensory loss associated with diabetic peripheral neuropathy, or nerve damage. By providing real-time alerts about plantar pressure distributions, or the area of pressure between the foot and the surface supporting it, users of the SurroSense Rx system can alter their activities in order to relieve unsafe pressures. The SurroSense Rx system is used in addition to current standard-of-care treatment for the prevention of plantar ulcers in diabetic patients. There is currently no available evidence that using the SurroSense Rx system prevents plantar ulcers. However, there are ongoing clinical trials that may identify patient populations that will benefit from its use.

 

Over time, high blood sugar in people living with diabetes causes damage to the peripheral nerves — the nerves that serve the arms, hands, legs, and feet. This damage, called diabetic peripheral neuropathy, includes symptoms such as painful tingling or burning sensations in the hands and feet, and the loss of protective sensations such as feeling pain or temperature changes. When pain sensation is lost, there is an increased risk of developing open sores caused by prolonged pressure or other injuries … read more

APHB: SUCCESSFUL CASE REPORTS PRESENTED FOR AB-SA01 AND AB-PA01

Multiple Case Reports Presented for Patients Treated with AB-SA01 and AB-PA01



On June 7, 2018, AmpliPhi Biosciences Corp. (NYSE:APHB) reported that multiple case reports on patients treated with the company’s lead bacteriophage development products, AB-SA01 and AB-PA01, were presented at the American Society of Microbiology (ASM) Annual Meeting and the 41st European Cystic Fibrosis Conference. Topline results from these cases had previously been announced by AmpliPhi with the presentations providing additional details.

At ASM, a presentation described four cases of severe Staphylococcus aureus infection treated with AB-SA01. Three of the cases involved patients with endovascular infection and one case of severe vertebral osteomyelitis with epidural abscess. For all the patients, medical and surgical therapy options had been exhausted. Patients were treated with 3×109 plaque-forming units of AB-SA01 intravenously twice-daily for two weeks in combination with the best antibiotic therapy available. The bacteriophage therapy was well tolerated in all patients with no reports of serious adverse events … read more

Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage

HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage (WCA), the nation’s leading wound care consulting firm has added the Aurix® System to its formulary. Founded in 2002, Wound Care Advantage (WCA) has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds.

“Diabetic foot ulcers pose a significant risk to patients and can be challenging for wound care centers to treat from both clinical and financial perspectives,” commented Dave Hazard, Nuo’s Vice President of Sales. “With thousands of commercially available wound care products, it can be extremely difficult for wound care centers to identify products that are both reimbursed by Medicare, and more importantly, that actually heal patients. We are excited to partner with Wound Care Advantage’s team of experts who rigorously vet each product that is placed on the formulary.”

The Platelet Rich Plasma gel produced by the Aurix System is cleared by the FDA for treating chronic wounds with a simple one-minute spin. In a clinical study performed with the Centers for Medicare and Medicaid Services (CMS), the Aurix System demonstrated a higher healing rate and a significant time to heal advantage as compared to other advanced healing modalities.

About Nuo Therapeutics

Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape. The Company’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to the Company’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward- looking statements. These risks, uncertainties, and factors are discussed under “Risk Factors” and elsewhere in the Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. The Company expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

Contact:
David Jorden
djorden@nuot.com